Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 1 of 66 09 May 2022 
 Clinical Study Protocol  
A Phase 2, Placebo -Controlled, Randomized, Blinded Study to Evaluate the 
Safety, Tolerability and Preliminary Efficacy of ARD -101 in Adults with 
Obesity  
 
Sponsor:  Aardvark Therapeutics  
4747 Executive Drive, Suite 102 0 
San Diego, CA 921 21 
Sponsor Study  Number:  AARD -201 
IND Number:  142288  
IMP Name:  ARD -101 
Development Phase:  Phase 2 
Version (Date) of Protocol:  
Amendment 1  
Amendment 2  
Amendment 3  
Amendment 4  
Amendment 5  1.0 (18 December 2020)  
2.0 (12 March 2021)  
3.0 (28 May 2021)  
4.0 (21 Octo ber 2021)  
5.0 (17 December 2021)  
6.0 (09 May 2022)   
 
 
 
 
This clinical study will be conducted in accordance with the International Council for Harmoni zation Tripartite 
Guideline for Good Clinical Practice (GCP) E6 (R2), the protocol and with other applicable regulatory requirements.  
Confidentiality Statement  
This document contains confidential information of Aardvark Therapeutics . Do not copy or distribute without written 
permission  from the Spons or. 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 2 of 66 09 May 2022 
 SIGNATURE PAGE  
Declaration of Sponsor  
Protocol Title:  A Phase 2, Placebo -Controlled, Randomized, Blinded Study to Evaluate the 
Safety, Tolerability and Preliminary Efficacy of ARD -101 in Adults with Obesity  
This clinical study protocol was subjected to critical review. The information it contains is 
consistent with current knowledge of the risks and benefits of the investigational medicinal product 
(IMP), as well as with the moral, ethical and scientific principles governing clinical research as set 
out in the guidelines  on GCP applicable to this clinical study.  
 
Sponsor Signatory  
 
 
Zhenhuan Zheng, PhD  
EVP of Research and Scientific Affairs  
Aardvark Therapeutics, Inc.   Date  
 
May 12, 2022
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 3 of 66 09 May 2022 
 SIGNATURE PAGE  
Declaration of Sponsor  
Protocol Title:  A Phase 2, Placebo -Controlled, Randomized, Blinded Study to Evaluate the 
Safety, Tolerability and Preliminary Efficacy of ARD -101 in Adults with Obesity  
This clinical study protocol was subjected to critical review. The information it contains is 
consistent with curr ent knowledge of the risks and benefits of the investigational medicinal product 
(IMP), as well as with the moral, ethical and scientific principles governing clinical research as set 
out in the guidelines on GCP applicable to this clinical study.  
 
Sponsor Signatory  
 
 
Andreas Niethammer, MD, PhD  
Chief Medical Officer  
Aardvark Therapeutics, Inc.   Date  
 
 
12MAY2022
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 4 of 66 09 May 2022 
 SIGNATURE PAGE  
Declaration of the Principal Investigator  
Protocol Title:  A Phase 2, Placebo -Controlled, Randomized, Blinded Study to Evaluate the 
Safety, Tolerability and Preliminary Efficacy of ARD -101 in Adults with Obesity  
This clinical study protocol was subjected to critical review and has been released by the Sponsor. 
The information it contains is consistent with current risk and benefit evaluat ion of the IMP, as 
well as with the moral, ethical and scientific principles governing clinical research as set out in the 
guidelines on GCP appl icable to this clinical study.  
 
Principal Investigator   
 
 
Principal Investigator  
  Signature  
 
Date  
  Site Number  
 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 5 of 66 09 May 2022 
 TABLE OF CONTENTS  
SIGNATURE PAGE  ................................ ................................ ................................ ......................  2 
SIGNATURE PAGE  ................................ ................................ ................................ ......................  3 
SIGNATURE PAGE  ................................ ................................ ................................ ......................  4 
TABLE OF CONTENTS  ................................ ................................ ................................ ................  5 
List of Tables  ................................ ................................ ................................ .....................  7 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  ................................ ...................  8 
1. PROTOCOL SUMMARY ................................ ................................ ...............................  11 
1.1. Protocol Synopsis  ................................ ................................ ...............................  11 
1.2. Schema  ................................ ................................ ................................ ...............  16 
1.3. Schedule of Asses sments, Time Points, and Window Allowance  .....................  17 
2. INTRODUCTION  ................................ ................................ ................................ ...........  19 
2.1. Background ................................ ................................ ................................ .........  19 
2.2. Risk-benefit Assessment  ................................ ................................ ....................  21 
2.2.1.  Known Potential Risks ................................ ................................ ....................  21 
2.2.2.  Known Potential Benefits  ................................ ................................ ...............  21 
2.3. Summary of Findings from Non -clinical, in vitro Studies with Potential 
Clinical Relevance  ................................ ................................ ..............................  22 
2.3.1.  Non-clinical Pharmacology  ................................ ................................ ............  22 
2.3.2.  Non-clinical Pharmacokinetics  ................................ ................................ ....... 22 
2.3.3.  Non-Clinical Safety Pharmacology and Toxicology  ................................ ...... 24 
2.4. Summary of Findings from Previous Clinical Studies  ................................ ....... 25 
2.4.1.  Overview of Clinical Pharmacology  ................................ ...............................  26 
2.4.2.  Overview of Clinical Efficacy  ................................ ................................ ........  28 
2.4.3. Overview of Clinical Safety  ................................ ................................ ...........  28 
2.4.4.  Benefits and Risks Conclusions  ................................ ................................ ...... 30 
3. STUDY ENDPOINTS  ................................ ................................ ................................ ..... 31 
3.1. Primary Endpoint ................................ ................................ ................................  31 
3.2. Secondary Endpoints  ................................ ................................ ..........................  31 
3.3. Exploratory Endpoints  ................................ ................................ ........................  31 
4. STUDY DESIGN  ................................ ................................ ................................ ............  33 
4.1. Overview  ................................ ................................ ................................ ............  33 
4.2. Justification for Dose  ................................ ................................ ..........................  33 
4.3. Study Duration ................................ ................................ ................................ .... 33 
4.4. Study Completion  ................................ ................................ ...............................  34 
4.5. Early T ermination  ................................ ................................ ...............................  34 
5. STUDY POPULATION  ................................ ................................ ................................ .. 35 
5.1. Number of Subjects  ................................ ................................ ............................  35 
5.2. Inclu sion Criteria  ................................ ................................ ................................  35 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 6 of 66 09 May 2022 
 5.3. Exclusion Criteria  ................................ ................................ ...............................  36 
5.4. Restrictions  ................................ ................................ ................................ .........  38 
5.4.1.  Dietary and Fluid Restrictions  ................................ ................................ ........  38 
5.4.2.  Lifestyle Considerations  ................................ ................................ .................  38 
6. INVESTIGATIONAL MEDICINAL PRODUCT  ................................ ..........................  39 
6.1. Premedication  ................................ ................................ ................................ ..... 39 
6.2. Identity of the Investigational Medicinal Products  ................................ ............  39 
6.3. Supply, Packaging, Labeling and Storage  ................................ ..........................  39 
6.4. Drug Accountability, Dispensing and Destruction  ................................ .............  39 
6.5. Dose Modification  ................................ ................................ ..............................  40 
6.6. Stopping Rules ................................ ................................ ................................ .... 40 
6.7. Subject Identification ................................ ................................ ..........................  41 
6.7.1.  Screening Numbers  ................................ ................................ .........................  41 
6.7.2.  Enrollment Numbers  ................................ ................................ .......................  41 
6.8. Com pliance  ................................ ................................ ................................ .........  41 
6.9. Special Precautions and Management of AEs  ................................ ....................  41 
6.9.1.  Eating disorders  ................................ ................................ ..............................  41 
6.9.2.  Allergic reactions  ................................ ................................ ............................  41 
6.9.3.  Management of gastrointestinal disorders  ................................ ......................  42 
6.9.4.  Embryo -fetal Toxicity ................................ ................................ .....................  42 
6.10.  Concomitant Therapy  ................................ ................................ .........................  42 
6.10.1.  Permitted Medications/Procedures  ................................ ................................ . 42 
7. DISCONTINUATION  ................................ ................................ ................................ .... 43 
7.1. Subject Withdrawal and Replacement  ................................ ................................  43 
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ...........................  44 
8.1. Eligibility Screening  ................................ ................................ ...........................  44 
8.2. Safety Variables ................................ ................................ ................................ .. 44 
8.2.1.  Adverse Events  ................................ ................................ ...............................  44 
8.2.2.  Clinical Laboratory Assessments  ................................ ................................ .... 49 
8.2.3.  Vital Signs  ................................ ................................ ................................ ...... 49 
8.2.4.  Standard 12 -lead Electrocardiograms  ................................ .............................  49 
8.2.5.  Bioimpedance  ................................ ................................ ................................ . 49 
8.2.6.  MRI PDFF and Full Body Composition Scan  ................................ ................  50 
8.2.7.  Mixed Meal Tolerance Test (MMTT)  ................................ ............................  50 
8.2.8.  Indirect Calorimetry  ................................ ................................ ........................  50 
8.2.9.  Physical Examinations  ................................ ................................ ....................  50 
8.2.10.  Continuous Glucose Monitoring  ................................ ................................ ..... 51 
8.2.11.  Circulating Hormones  ................................ ................................ .....................  51 
8.2.12.  Fecal Microbiome Analysis  ................................ ................................ ............  51 
8.2.13.  Non-invasive Phenotypic Bitter Taste Test  ................................ ....................  52 
9. STATISTICAL CONSIDERATIONS  ................................ ................................ ............  53 
9.1. Study Population  ................................ ................................ ................................  53 
9.1.1.  Protocol Deviations  ................................ ................................ ........................  53 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 7 of 66 09 May 2022 
 9.2. General Considerations  ................................ ................................ ......................  53 
9.3. Subject Disposition  ................................ ................................ .............................  53 
9.4. Demographic and Anthropometric Information and Baseline Characteristics ... 53 
9.5. Prior and Concomitant Medication and Drug Administration  ...........................  54 
9.6. Exposure  ................................ ................................ ................................ .............  54 
9.7. Safety Analyses  ................................ ................................ ................................ .. 54 
9.7.1.  Adverse Events  ................................ ................................ ...............................  54 
9.7.2.  Clini cal Laboratory Tests ................................ ................................ ................  55 
9.7.3.  Vital Signs  ................................ ................................ ................................ ...... 55 
9.7.4.  Standard 12 -lead Electrocardiogram  ................................ ..............................  55 
9.7.5.  Physical Examination  ................................ ................................ .....................  55 
9.8. Exploratory analysis  ................................ ................................ ...........................  55 
9.9. Determination of Sample Size  ................................ ................................ ............  55 
10. ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS  ................................ ..........  56 
10.1.  Data Quality Assurance  ................................ ................................ ......................  56 
10.2.  Data Collection and Access to Source Data/Documents  ................................ .... 56 
10.3.  Archiving Study Documents  ................................ ................................ ..............  56 
10.4.  Good Clinical Practice  ................................ ................................ ........................  57 
10.5.  Informed Consent  ................................ ................................ ...............................  57 
10.6.  Insurance and Compensation for Injury  ................................ .............................  58 
10.7.  Protocol Approval and Amendment(s)  ................................ ...............................  58 
10.8.  Confidentiality Data Protection  ................................ ................................ ..........  58 
10.9.  Publication Policy  ................................ ................................ ...............................  59 
11. REFE RENCE LIST  ................................ ................................ ................................ .........  60 
12. APPENDIX  ................................ ................................ ................................ .....................  61 
 
List of Tables  
Table 1  Schedule of Assessments  ................................ ................................ .........................  17 
Table 2  Caco -2 cell Monolayer Permeability of ARD -101, Warfarin, Ranitidine and 
Talinolol  ................................ ................................ ................................ ...................  20 
Table 3  The Pharmacokinetic Parameters of ARD -101 After Single Intravenous or 
Intragastric Administration to Cynomolgus Monkeys  ................................ .............  23 
Table 4   Geometric Mean (%CV) PK Parameters of ARD -101 Following Single Oral 
Dose Administration of ARD -101 ................................ ................................ ...........  26 
Table 5   Geometric mean (%CV) PK parameters of ARD -101 BID oral dose 
administration of ARD -101 for 14 days ................................ ................................ ... 28 
Table 6  Summary of Treatment -emergent Adverse Events - MAD Part  ..............................  29 
Table 7  Summary of Treatment -related Treatment -emergent Adverse Evens by System 
Organ Class and Preferred Term - MAD Part  ................................ ..........................  30 
 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 8 of 66 09 May 2022 
 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
Abbreviation  Definition  
AE Adverse event  
ALT  Alanine aminotransferase  
AST  Aspartate transaminase  
AUC  Area under the curve   
AUC 0-τ Area under the plasma  concentration versus time curve from time zero to 
time τ  
b.i.d.  Twice a day  
BLQ Below the quantitation limi t 
BMI  Body mass index  
bpm Beats per minute  
CBC  Complete blood count  
CCK  Cholecystokinin  
CFR Code of Federal Regulations  
CGM  Continuous glucose monitoring  
CHO  Carbohydrate  
CL Systemic clearance  
Cmax Maximum observed concentration  
CNS Central nervous system  
CoEQ  Control of Eating Questionnaire  
CRO Contract research organi zation  
CRP  C-reactive protein  
CSR  Clinical study report  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CYP 450  Cytochrome P450  
ECG  Electrocardiogram  
eGFR  Estimated glomerular filtration rate  
EOS End of Study  
FIH First-in-Human  
F% Oral bioavailability  
FSH Follicle stimulating hormone  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 9 of 66 09 May 2022 
 Abbreviation  Definition  
GCP  Good Clinical Practice  
GI Gastrointestinal  
GIP Gastric inhibitory polypeptide  
GLP Good Laboratory Practice  
GLP -1 Glucagon -like peptide -1 
HbA1c  Glycated hemoglobin  
hERG  Human ether -a-go-go-related gene  
HOMA -IR Homeostatic model assessment for insulin resistance  
HPBL Human peripheral blood lymphocytes  
ICF Informed consent form  
ICH International Council on Harmonization  
IC50 Half maximal Inhibitory Concentration  
IEC Independent ethic committee  
i.g. Intragastric  
IgE Immunoglobulin E 
IMP Investigational medicinal product  
IL Interleukin  
IP Intraperitoneal  
IND Investigational new drug 
IRB Institutional review board 
i.v. Intravenous  
MATE  Multidrug and toxic compound extrusion  
MDRI  Multi-drug resistance -1 
MedDRA  Medical Dictionary for Regulatory Activities  
MMTT  Mixed Meal Tolerance Test  
MRI -PDFF  Magnetic resonance imaging -derived proton density fat fraction  
NASH  Nonalcoholic steatohepatitis  
NOAEL  No observable adverse effect level  
OAT3  Organic anion transporter  3 
OCT2  Organic cation transporter 2  
OGTT  Oral glucose tolerance test  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 10 of 66 09 May 2022 
 Abbreviation  Definition  
OTC  Over -the-counter  
PK Pharmacokinetics  
p.o. per. os  (oral ly) 
PYY  Peptide YY  
QTcB  QT interval corrected for heart rate using Bazett’s correction  
QTcF  QT interval corrected for heart rate using Fridericia’s correction  
SAE  Serious adverse event  
SD Standard deviation  
SMC Safety Monitoring Committee  
SOC System organ class  
SOP Standard operating procedure  
SUSAR  Suspected unexpected serious adverse reaction  
t1/2 Terminal elimination half -life calculated as: ln2/λz  
tmax Time of the maximum observed concentration  
TEAEs  Treatment -emergent adverse events  
TNF Tumor necrosis factor  
TSH  Thyroid -stimulating hormone  
ULN  Upper limit of normal  
US United States  
Vd Volume of distribution  
Vss Volume of distribution at steady state  
WHO  World Health Organization  
WHO -DD WHO Drug Dictionary  
 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 11 of 66 09 May 2022 
 1. PROTOCOL SUMMARY  
1.1. Protocol Synopsis  
Protocol Title  A Phase 2, Placebo -Controlled, Randomized, Blinded Study to Evaluate the 
Safety, Tolerability and Preliminary Efficacy of ARD -101 in Adults with 
Obesity  
Study Number  AARD -201 
Development Phase  Phase 2 
Sponsor  Aardvark Therapeutics , Inc.  
Study Center  The study will be conducted at a single center  in the United States  (US) 
Study Endpoints  Primary Endpoint : 
• The percent total weight change at the end of treatment from baseline  
 
Secondary Endpoints:  
• Safety and tolerability of ARD -101 by assessment of the incidence of 
treatment -emergent adverse events (TEAE)  
• The change in blood lipid concentrations (total cholesterol, triglyceride, 
high density lipoprotein cholesterol, and low -density lipoprotein cholesterol) 
at the end of treatmen t from the baseline  
• The change in waist circumference at the end of treatment from the 
baseline  
• The change in hemoglobin A1c (HbA1c) at the end of treatment from the 
baseline  
 
Exploratory Endpoints : 
• Categorical weight loss. Proportion of subjects who los e < 5% and  ≥ 5%  
initial weight  
• Fasting c irculating  levels of glucagon -like peptide (GLP )-1 (total and 
active) , cholecystokinin (CCK), peptide YY (PYY ), amylin, glucose -
dependent insulinotropic polypeptide (GIP)  (total and active) , ghrelin , leptin, 
and adiponectin before the first dos ing, and at 1h and 2h after the first dos ing 
on day 1  
• Change s in response to mixed -meal tolerance test (MMTT) , including:  
▪ Serum levels of  glucose, insulin, and C-peptide prior  to 
(negative timepoints) and post  (positive timepoints)  the Ensure 
meal given for MMTT  at baseline (run -in visit)  and on day 28 .  
▪ Serum level of f ree fatty acids (FFA ) prior to (negative 
timepoints) and post (positive timepoints) the Ensure meal given 
for MMTT  at baseline (run -in visit) and on day 28  
▪ Circulating level s of GLP -1 (total and active), CCK, PYY, 
amylin, GIP (total and active) , glucagon, and ghrelin prior to 
(negative timepoints) and post (positive timepoints) the Ensure 
meal given for MMTT  at baseline (run -in visit) and on day 28  
▪ Circulating  cytokines and inflammatory markers such as C-
reactive protein (CRP ) at run-in visit  and end of treatment  (day 
28) performed during the MMTT  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 12 of 66 09 May 2022 
 ▪ Circulating levels of bile acids, ferritin, leptin, and adiponectin 
at run -in visit and end of treatment (day 28) performed during 
the MMTT  
• Body composition as measured by bioelectrical impedance scal e 
• Body composition and hepatic steatosis by magnetic resonance imaging -
derived proton density fat fraction (MRI -PDFF ) + full body composition scan  
at pretreatment and end of treatment  
• The change in homeostatic model assessment for insulin resistance  
(HOMA -IR) at the end of treatment from the baseline   
• The change in fasting blood glucose at the end of treatment from the 
baseline   
• Hunger and control of eating as measured by Likert  and visual analogue 
scales , respectively  
• Change in indirect calorimetry  
• The fecal samples will be  collected  during the run -in visit and on day 28 
for microbiome analy sis to evaluate potential effects of the study medication  
on fecal microbiome profile  (optional for subjects)  
• Phenotypic  bitter  taste test (using com mercially available test strips/kits) 
during the run -in visit  of the study ( optional for subject s) 
Study Design  This is a  Phase 2, randomized, placebo -controlled, single -blind ed study  of 
ARD -101 in obese subjects  with Body Mass Index (BMI ) of 30 -45 kg/m2. 
 
A total of approximately 30 subjects will be randomized in a 2:1 ratio .  
 
A screening process will be initiate d upon completion of the informed consent 
process. Subjects will be assessed for eligibility through screening tests 
conducted within 28 days  prior to enrollment . Following completion of 
screening tests and confirmation of eligibility, subjects will be randomized to 
receive ARD -101 or placebo .  
 
All available safety , tolerability  and preliminary efficacy data will be 
evaluated throughout study conduct. P harmacodynamic  data will be analyzed 
after study completion.  
 
Subjects will be receiving treatment in an outpatient setting  and will be  
instructed to visit the clinical center periodically as scheduled in Table 1 for 
safety and efficacy assessments. The treatment may be discontinued due to 
intolerable toxicity, withdrawal of informed consent, discretion of pr incipal 
investigator or end of the study.  
 
All subjects will be followed up for 14 days  after the last dose of study drug.  
Test Product, Dose, and Mode of 
Administration  ARD -101 200 mg BID administered orally for 28 days  
Inclusion Criteria  Subjects must  meet all the following criteria to be eligible for participation in 
this study:  
 
1. Male  and female subjects, 18 -75 years of age  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 13 of 66 09 May 2022 
 2. Willing and able to provide signed and dated informed consent prior to 
any study -related procedures and willing and able to comply with all study 
procedures  
3. BMI of 30-45 kg/m2 
4. Stable body weight by subject report ( ± 5%) in the previous 6 months 
prior to randomization  
5. No abnormal findings or abnormalities of clinical significance in vital 
signs, physical examination, clinical laboratory tests ( complete blood 
count ( CBC ), urinalysis, blood biochemistry, coagulation, pregnancy test 
(females  of child bearing potential ), urine drug test, nicotine test, etc.), 
12-lead electrocardiogram ( ECG ) during the Screening Period.  
6. Serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate 
aminotransferase, alanine aminotransferase) and total bilirubin (unless the 
subject has documented Gilbert syndrome) not exceeding 1.5-fold the 
upper laboratory norm  and estimated glomerular f iltration rate (eGFR ) 
>30 mL/min 
7. Standard 12 -lead ECG parameters after 10  minutes resting in supine 
position in the following ranges; 120 ms <PR <220 ms, QRS <120 ms, 
QTc ≤ 430 ms if male, ≤ 450 ms if female , and normal ECG tracing unless 
the Investigator considers an ECG abnormality within described limits to 
be not clinically relevant  
8. Stable or well controlled blood pressure per Investigator’ s judgement 
during the Screening Period. Specifically: Vital signs after 10 minutes 
sitting in a chair (feet on flo or, back supported):  
i. 95 mmHg <systolic blood pressure (SBP) <160 mmHg,  
ii. 45 mmHg <diastolic blood pressure (DBP) <100 mm Hg,  
iii. 40 bpm <heart rate (HR) <100 bpm  
9. Prediabetes - defined as a fasting blood glucose between 100 -125 mg/d L 
OR an HbA1c betwee n 5.7 -6.5% at screening  
10. Type 2 diabetes - Defined as previous diagnosis by a healthcare 
professional OR a fasting blood glucose > 126 mg/d L OR HbA1c > 6.5% 
at screening.   
11. Patients with type 2 diabetes treated with metformin may be enrolled.  
However, patients with type 2 diabetes on any other therapy will be 
excluded.   
12. Female subjects must have negative pregnancy test and must not be 
lactating. For females able to bear chi ldren, a hormonal (i.e., oral, 
implantable, or injectable) and single barrier method (i.e., sponge), or a 
double -barrier method of birth control (i.e., condom with spermicide) or 
abstinence must be used/practiced throughout the study and for 90 days 
follow ing last dose of study medication; for effective form of birth 
control.  
13. Females of non -childbearing potential, defined as surgically sterile (status 
post hysterectomy, bilateral oophorectomy, bilateral tubal ligation, 
bilateral salpingectomy, or bilateral tubal occlusion) or post -menopausal 
for at least 12 months (may be confirmed with a screening follicle 
stimulating hormone (FSH) level in the post -menopausal lab range), do 
not require contraception during the study.  
14. Males with female partners of childbear ing potential must agree to a 
double -barrier method if they become sexually active during the study and 
for 90 days following the last dose of the study medication. Male subjects 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 14 of 66 09 May 2022 
 must not donate sperm for 90 days following their participation in the 
study.  
Exclusion Criteria  Subjects who meet any of the following criteria will be excluded from study 
participation:  
 
1. History of significant drug hypersensitivity or anaphylaxis  
2. Prior bariatric or GI surgery (excluding cholecystectomy , 
hysterectomy  or appendectomy)  
3. Participation in a weight loss program or clinical trial for weight 
loss within 30 da ys prior to randomization  
4. Diabetes  treatment  (unless metformin as outlined) , or chronic oral 
steroids,  or treatment with  immune modulators, anti -obesity drugs, 
chronic opiate therapy , or antipsychotic  medications .   
5. Received any experimental drugs or devices or have participated in 
a clinical study within 30 days prior to randomization  
6. Currently receiving any drug -based therapy for weight management  
7. Thyroid -stimulating hormone ( TSH ) level is outside of normal limit  
8. The presence of diseases with abnormal clinical manifestations that 
need to be excluded based on their possible contributio n to weight 
loss or weight gain, including but not limited to nervous, 
cardiovascular, blood and lymphatic system, immune, renal, 
hepatic, gastrointestinal, respiratory, metabolic and skeletal diseases  
9. History of myocardial infarction, unstable angina, art erial 
revascularization, stroke, New York Heart Association Functional 
Class II -IV heart failure, or transient ischemic attack within 6 
months prior to Visit 1  
10. Any malignancy not considered cured (except focal, treated basal 
cell carcinoma and squamous cell carcinoma of the skin); a 
participant is considered cured if there has been no evidence of 
cancer recurrence in the previous 5 years  
11. History of major depressive disorder or history of other severe 
psychiatric disorders (e.g., schizophrenia or  bipolar disorder) within 
the last 2 years.  
12. Major surgery within 3 months prior to randomization or planned 
surgery during the study  
13. Donated ≥200 mL of blood (blood components) or had massive 
blood loss, received blood transfusion or blood products within 3 
months prior to randomization  
14. Planned sperm/egg donation within 6 months post randomization  
15. Positive urine drug test for any illicit non -prescription substances  
16. History of consuming more than 14 units of alcoholic beverages per 
week or of alcoholism or d rug/chemical/substance abu se within past 
2 years prior to enrollment (Note: one unit = 12 ounces of beer, 4 
ounces of wine or 1 ounce of spirits)  
17. Smoking any amount within 3 months prior to randomization  
18. Excessive  consumption of  tea, coffee , and/or caffeinated beverages 
(more than 8 cups, 250 m L for each cup) every day within 3 months 
prior to enrollment  
19. Symptomatic viral, bacterial (including upper respiratory infection), 
or fungal (non -cutaneous) infection within 1  week prior t o 
randomizati on 
20. History of human immunodeficiency virus antibody  or active 
hepatitis  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 15 of 66 09 May 2022 
 21. A history of psychiatric and psychological condition that, in the 
judgment of the investigator, may interfere with the planned 
treatment and follow -up, affect subject compliance or pl ace the 
subject at high risk from treatment -related complications  
22. Poor venous access or inability to tolerate venipuncture  
23. Any condition or active drug treatment that the investigator or 
primary physician believes may not be appropriate for participating 
in the study  
Duration of Study  The duration of participation for each subject will be approximately  84 days 
(12 weeks)  
• Screening Period: Up to 28 days (4 weeks)  
• Run-in Visit: Up to 14 days (2 weeks)  
• Treatment Period: 28 days on ARD -101 (4 weeks)  
• Follow -up Period: 14 days (2 weeks). The End of Study  (EOS)  Visit 
will occur within14 days after receiving the dose of ARD -101 
Pharmacodynamic Evaluation  All subjects will be required to provide blood samples at baseline, at defined 
time points and at the end of treatment visit. These blood samples will be used 
to explore the parameters described in the endpoint setting. The Control of 
Eating Questionnaire (CoEQ) will  be administered at the timepoints indicated 
in Table 1.  
Safety Evaluations  Adverse event s (AE) will be collected from the time of informed consent until 
14 days after the last administration of study drug. Safety laboratory 
assessments, including CBC, chemistries, coagulation tests, urinalysis, and 
thyroid function, along with ECGs, , and vital signs will be obtained. All 
concomitant medications will be recorded.  All adverse events will be followed 
to resolution or stabilization.  Only TEAE will be summarized . 
Efficacy Evaluations  The efficacy assessments include changes from baseline in body weight, BMI, 
waist circumference, insulin resistance, body fat percentage, HbA1c, serum 
glucose, lipids, ambulatory blood pressure and defined hormone 
concentrations.  
Statistical Analysis  All safety, and efficacy data will be summarized and presented overall for the 
study, using descriptive statistics. Mean, median, standard deviation, 
minimum, and maximum will be presented for continuous variables and   
frequencies and percentages for discrete variables.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 16 of 66 09 May 2022 
 1.2. Schema  
 
 
Assessed for eligibility  
Enrollment  
Randomization  
(N = 30)  
Follow up  
(14 days)  
Follow up  
(14 days)  
ARD -101 
(N = 20)  
200 mg BID X 28 days)  
 
Placebo  
(N = 10)  
(BID X 28 days)  
 
Analyzed  
 Analyzed  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 17 of 66 09 May 2022 
 1.3. Schedule of Assessments, Time Points , and Window Allowance  
Details on procedures and timing of assessments are presented in  Table 1. 
Table 1 Schedule of Assessments  
Period  Screening  Run- in Visit  Treatment Period  
(±3 days)  Follow Up/End of 
Study  
Study Days  -42 to -15 14 days prior to day 1  1a 15 28 14 
Informed Consent  X      
Inclusion/ Exclusion Criteria  X      
Demographics  X      
Medical History  X      
Randomization    X    
Physical Examinationb X  X X X X 
Vital Signs  X X X X X X 
12-lead ECG  X  X  X  
Hematology  X  Xc   X 
Comprehensive Serum Chemistry  X  Xc X X X 
Urinalysis  X     X 
Urine Toxicology  X      
Coagulation Parameters  X  Xc   X 
Pregnancy Testd X  X   X 
TSH  X      
Weight/BMI  X X X X X X 
Bioimpedance    X X X  
MRI PDFF + Full Body Composition Scan  X   X  
Height  X      
Fasting Glucose   X   X  
HbA1c  X    X  
Waist Circumference    X X X X 
Fasting Blood Lipids   X   X  
Fasting Circulating  Hormonese   X    
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 18 of 66 09 May 2022 
 Period  Screening  Run- in Visit  Treatment Period  
(±3 days)  Follow Up/End of 
Study  
Study Days  -42 to -15 14 days prior to day 1  1a 15 28 14 
Study Drug Dispensation    Xf    
Concomitant Medication  X  X X X  
Adverse Event Monitoring  X  X X X X 
Mixed Meal Tolerance Test (MMTT)   X   X  
CGM Placement   X  X   
CGM Removal and Download    X  X  
Indirect Calorimetry   X   X  
Fecal Sample Collectiong  X   X  
Phenotypic Bitter Taste Testh  X     
Control of Eating Questionnaire (CoEQ)  X  X X X  
a. Predose  
b. Complete physical examination at screening, and brief physical examination for all follow -up visits  
c. This procedure is not needed if performed within 3 days  
d. For women of child -bearing potential only  
e. GLP -1 (total and active) , CCK, PYY, amylin, GIP (total and active ), ghrelin,  leptin, and adiponectin  in all subjects at 3 time points (before the first dosing 
and 1h as well as 2h  after the first dosing ) 
f. A single oral dose of ARD -101 will be administered to subject in the morning of day 1 
g. During run -in visit  and on day 28 . Optional for subjects  
h. Phenotypic bitter taste test is optional for sujects  
 
 
  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 19 of 66 09 May 2022 
 2. INTRODUCTION  
2.1. Background  
Obesity  
Obesity is a chronic disease with a multifactorial etiology including behavioral , environmental, 
sociocultural, physiological and genetic factors. obesity and its consequences  are an increasing 
burden globally . Obes e, defined as a BMI>3 0 kg/m2, is an established risk factor for a number of 
diseases such as hypertension, cardiovascular disease, cancer s, diabetes type 2, and many others  
(Guh DP et al. 2009 ). Currently, there are an estimated 600 million obese people wo rldwide 
(Collaborators GBDO et al. 2017 ). BMI data shows that about 40% of American adults are obese  
(Hruby A and Hu FB 2015 ), while worldwide, about 3.4 million annual deaths are directly 
attributed to obesity  (Collaborators GBDO et al. 2017 ).  
The treatment of obesity involves lifestyle changes, bariatric surgery and pharmacotherapy (Bray 
GA et al. 2016 ). Lifestyle change, including diet and exercise, requires considerable patient 
commitment, and has poor complian ce. Surgery is expensive and invasive. Pharmacotherapy, 
therefore, is the primary option for the majority of patients. A variety of drugs are designed to 
prevent food absorption, decrease appetite, or increase metabolism. Compared to controls, most 
drugs c ause weight loss of <4 kg with substantial severe adverse events (Rosa -Goncalves P and 
Majerowicz D 2019 ). Some of the adverse events have cau sed withdrawal of a number of drugs 
from the market in several countries (Rodgers RJ 2017 ). As a result, a significant portion of obese 
patients have no treatment options due to adverse events and limit ed weight loss. Taken together, 
obesity remains an unmet medical need and development of new compounds that are safe and 
effective is paramount.  
Denatonium  
Denatonium is one of the bitterest tastants  among tens of thousands of natural or synthesized bitter 
compounds, with a bitterness detection threshold of 0.05 ppm. To date, one of the denatonium 
salts, denatonium benzoate has been approved as an additive to household products  to prevent the 
ingestion of potentially harmful substances through taste aversi on (Sibert JR and Frude N 1991 ). 
Importantly, the US Consumer Product  Safety Commission has judged  denatonium benzoate as 
generally safe.  Like other bitter compounds, denatonium can strongly activate  up to 25 G -protein 
coupled receptors express ed in a variety of tissues  and organs including GI tract, pancreas, fat, 
trachea, and central nervous system . Bitter taste receptors  are thought to b e evolutionarily 
conserved for the detection  of potentially toxic compounds.  Activation of b itter receptors  in the 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 20 of 66 09 May 2022 
 mouth elicits a familia r aversive sensation,  while  activation of b itter receptors  in the gut and 
chemoreceptor trigger zone located in the m edulla leads to  reduction of appetite and delayed  
gastric emptying as well as other adaptations. In a number of animal studies, denatonium benzoate 
has been shown to inhibit ongoing ingestive behavior , suppress food intake, and inhibit gastric 
emptying (Janssen S et al. 2011; Schier LA et al. 2011 ). Moreover, denatonium benzoate can 
stimulate the release of GLP -1 and CCK that are known to cause satiety and satiation (Chen MC 
et al. 2006; Kim KS et al. 2014 ). In human studies, the intragastric administration of denatonium 
benzoate after a liquid  meal has been reported to inhibit relaxation of the proximal stomach. While 
in an oral nutrient tolerance test, denatonium benzoate was shown to increase satiation (Avau B et 
al. 2015 ). In a clinical trial conducted in healthy female volunteers, intragastric administration of 
denatonium b enzoate is shown to decrease both antral motility and hunger ratings during the 
fasting state, probably via inhibiting motilin release. More importantly, no adverse reactions have 
been reported in all these human studies (Deloose E et al. 2017 ). Taken together, intragastric 
administration of denatonium salts is safe and can lead to weight los s by changing the appetite and 
eating behaviors  and therefore, are promising agents for the treatment of obesity.  
Rationale of the Study  
ARD -101 is an encapsulated oral formulation of denatonium  acetate salt that  is designed to b ypass 
the oral taste receptors  when administered orally . Aardvark Therapeutics has demonstrated the 
efficacy  and safety of ARD -101 in multiple preclinical animal models  of metabolic disorders and 
weight management . The safety as well as pharmacokinetics have been confirmed in a human trial.  
In addition, ARD -101 is minimally absorbed into the circulation through the GI epithelium cells 
provided the very low cellular penetration rate as demonstrated by the Caco -2 cell monolayer 
permeability assay ( Table 2). 
Table 2 Caco -2 cell Monolayer Permeability of ARD -101, Warfarin, Ranitidine and 
Talinolol   
 
 Compounds  Papp (10-6 cm/s)  Efflux ratio  A→B  B→A  
ARD -101 (10 µM)  0.378  4.65 12.3 
Ranitidine  0.355  0.812  2.29 
Warfarin  34 31 0.913  
Talinolol  0.337  5.03 14.9 
Talinolol + Verapamil  0.737  1.51 2.05 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 21 of 66 09 May 2022 
 Taken together, ARD -101 has demonstrated promising preclinical activity  in models of metabolic 
syndrome  and a manageable toxicity profile  in humans .  
For details of the preclinical results, please refer to the Investigator Brochure.  
2.2. Risk -benefit Assessment  
2.2.1.  Known Potential  Risks  
ARD -101 has shown a well -tolerated safety profile with no significant organ toxicities up to 200 
mg/kg /day in a GLP -compliant pivotal toxicology study with cynomolgus monkeys.   As with any 
new drug, rare or unexpected side effects could occur. The ARD -101 related  toxicities may be 
mild to severe, including adverse hypersensitivities, or adverse reaction in GI system . 
Additionally, comprehensive non -clinical toxicology studies have been  performed to establish the 
toxicity profile of ARD -101. The Cynomolgus monkey was identified as the pharmacologically 
relevant species for assessing human risk of ARD -101. ARD -101 was tolerated in a 
GLP -compliant, 28-day repeat -dose toxicology study  in Cynomolgus monkey where systemic 
exposure was confirmed in all animals.  
No denaton ium salt has been approved for treatment in subjects for any indication . Besides ARD -
101,denatonium benzoate is currently the only denatonium salt  that has been tested in humans. 
The potential risks that may be associated with ARD -101 are considered to be similar to 
denatonium benzoate , which have been shown to be well -tolerated when administered p.o. (orally)  
with no reported adverse reaction (Deloose E et al. 2017 ). Taken together, denatonium salt  is safe 
and well -tolerated when administered  p.o. in humans.  
ARD -101 has been studied  for its safety and pharmacokinetics  in humans  with the results in detail 
summarized below. In short, ARD -101 has been found to be safe at a dose level of up to 240  mg 
BID for 14 days and the PK has confirmed minimal systemic uptake and no  accumulation after 11 
days.  
2.2.2.  Known Potential Benefits  
Preclinically, ARD -101 was shown to reduce food and water consu mption within 2 hours after 
dosing  in SD rats. ARD -101 exhibited significant attenuation of weight gain (compared to 
control mice) in high fat diet -induced obese mice model after 5 6 days of treatment.  ARD -101 
also exhibited nominal attenuation of wei ght gain in ob/ob mice models.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 22 of 66 09 May 2022 
 Further,  previous studies, i.g. (intragastric) administration of denatonium  helped in  mitigat ion of 
chronic  and acute  inflammation  in multiple  preclinical  models,  characterized  by improved  
pathology,  downregulation  of inflammatory  cytokines  (such  as IL-6, TNF,  IL-1β, etc.). Benefits  
were  also observed  with regards  to cholesterol  levels,  HbA1c  and other  metabolic  markers.  
In a 48-week  study  of diet-induced  NASH  in mice , dosing  with ARD -101 largely  abrogated  
development  of liver fibrosis  over control  based  on blinded  histopatho logic  review.  
2.3. Summary of Findings from Non -clinical , in vitro Studies with Potential Clinical 
Relevance  
An in vitro secondary pharmacology study was performed to evaluate the binding, enzyme, and 
uptake activity of 10  µM ARD -101 and assess the specificity of ARD -101 activity. The study 
tested ARD -101 binding to 27 receptors (including subtypes of monoaminergic, cannabinoid, 
histaminic, nicotinic, opioid, and glucocorticoid receptors), 3 transporters, 8 ion channels, and 
6 enzymes. Results from 2 assays, α1A  adrenergic receptor and hERG potassium ion channel 
assays, revealed an inhibition or stimulation higher than 50%, denoting a significant effect of 
ARD -101 in these two targets. The remaining assays did not show significant ARD -101 activity . 
2.3.1.  Non-clinical  Pharmacology  
Effect of ARD -101 to Support Proposed Indication  
The key data to support ARD -101 for  the treatment of obesity and metabolic syndrome  stems from 
preclinical experiments in multiple rodent models demonstrating benefit of oral dosing with ARD -
101 with regards to mitigation of weight gain as well as improvement in pathologies such as 
hypercholesterolemia, prediabetes and chronic inflammation.  
2.3.2.  Non-clinical  Pharmacokinetics  
The PK profile of ARD -101 was characterized in a panel of  in vitro  and in vivo  studies, including  
plasma protein binding assay s, permeability assays, metabolic stability  and metabolite 
identification assessment s, Cytochrome 450  (CYP450 ) phenotype assays , in vitro  drug-drug 
interaction studies on CYP450s , and serum/plasma toxicokinetic  studies in Cynomolgus monkey s.  
In the Caco -2 cell monolayer permeability assay , ARD -101 showed a low permeability through 
intestinal epithelia cell, the P app value of ARD -101 i n the apical  to basolateral  direction  was 
0.378×10-6 cm/s . In addition, ARD -101 exhibited efflux effect with an efflux ratio of about 12.3, 
indicating ARD -101 is a substrate of certain efflux transporters.   
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 23 of 66 09 May 2022 
 To investigate the PK of ARD -101 including  systemic exposure, oral bioavailability, and PK 
linearity , a non -GLP PK study was conducted in Cynomolgus monkeys. Three male Cynomolgus 
monkeys were assigned to 3 dose groups and a single dose of ARD -101 was administrated p.o. at 
0.49, 1.62, or 4.85 mg/kg (denatonium base weight). After a 14 -day washout period, an intravenous 
(i.v.) administration of ARD -101 was given to the same animal at the same dose level. Blood 
samples were collected from  all animals on Day 1 and Day 15 at 0.25, 0.5, 1, 2, 4 , 8, 24, 32, and 
48 h post-dose.   
Following a single i.v. dose of ARD -101 at 0.49, 1.62 , and 4.85  mg/kg to Cynomolgus monkey s, 
the C max and AUC 0-48h were 129, 803, 2270 ng/mL  and 270, 1460, 4720 ng*h/mL , respectively. 
The values of CL and V d were  2150, 1320, 1240 mL/h/kg and 32500, 25800, 17500  mL/kg, 
respectively. The elimination of ARD -101 in monkeys was slow, as indicated by the mean t1/2 of 
11.25  h. Within the dose range of 0.49 -4.85 mg/kg, AUC increased higher than dose proportional ly 
(Table 3).  
Following a single oral dose of ARD -101 at 0.49, 1.62 , and 4.85  mg/kg, the AUC 0-48h was 
insignificant and C max were  0, 1.98, 4.55  ng/mL , respectively, indicating an extremely low 
systemic exposure of ARD -101. The oral bioavailability (F%) in monkeys was estimated to be 0%  
at 0.49, 1.62, and 4.85 mg/kg, respectively.  No clinical abnormal signs were noticed given very 
low absorption and negli gible systemic exposure  (Table 3).  
In summary, the bioavailability of ARD -101 in monkey is negligible, no  systemic exposure 
reached after 4.85 mg/kg  p.o. administration .  
Table 3 The Pharmacokinetic Parameters of ARD -101 After Single Intravenous or 
Intragastric Administration to Cynomolgus Monkeys  
Route  Dose  
(mg/kg)  Cmax 
ng/mL  AUC 0-t 
ng*h/mL  t1/2 
hours  Tmax 
hours  CL mL/min/kg  VSS L/kg  F% 
i.v. 0.49 129 270 105 0.25 2150  32.5  
1.62 803 1460  13.5 0.25 1320  25.8  
4.85 2270  4720  9.74 0.25 1240  17.5  
p.o. 0.49 BLQ  NA NA NA NA NA 0 
1.62 1.98 NC NC 2 NA NA 0 
4.85 4.55 NC NC 1 NA NA 0 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 24 of 66 09 May 2022 
 Abbreviations: BLQ: below the quantitation limit; F: fraction (%) of an administered drug that reaches the systemic 
circulation [oral bioavailability] ; i.v.: intravenous administration; p.o.: orally administration;  NA: not applicable; 
NC: not calculable.  
Pharmacokinetic  parameters after repeated oral doses were obtained from the toxicokinetic study 
following b.i.d.  i.g. administration of 15, 30, or 100 mg/kg/dose of ARD -101 (denatonium base 
weight) to Cynomolgus monkeys for 28 days. After the first dose, the mean plasma  AUC and C max 
values were similar between male and female animals , indicating  a lack of sex-related differences 
in systemic exposure.  There was a trend toward  a greater than dose -proportional increase in  Cmax 
and AUC 0-24h. At Day 28, s teady  state mean AUC 0-24h value s were 26.3, 40.6, and 1210 ng*h/mL 
for female monkeys and 40.1, 48.0, and 1400  ng*h/mL  for male monkeys at 15, 30, and 
100 mg/kg/doses, respectively.  No accumulation  of ARD -101 in monkey s was observed  after 
4 weeks of b.i.d.  administration .  
ARD -101 exhibited low binding (<  50%) to human and rat plasma proteins, and a relatively high 
binding to monkey plasma proteins (50 % to 90%). An in vitro  liver microsome stability study 
showed that ARD -101 was quickly metab olized by rat liver microsomes, moderately by monkey 
microsomes, and almost no metabolism in human liver microsomes. Cytochrome P450s ( CYPs ) 
were not the major enzymes involved in ARD -101 metabolism . An in vitro  metabolite 
identification study showed that the N -dealkylated metabolite (M1, lidocaine) was only seen in the 
human  S9 samples  at trace level s, account ing for only 0.05% of total peak areas. The oxidation 
product  M2 was the major metabolite, account ing for 18.88%, 5.82% , and 0.31% of total peak 
areas in rat, monkey and human s, respectively.   
A probe substrate -based inhibition study in human liver microsome s showed that ARD -101 was a 
moderate inhibitor of CYP2D6 with an IC50 value of 0.233  µM. The CYPs induction study in 
human hepatocyte s showed  that ARD -101 was not a potential inducer of CYP1A2, CYP2B6 , and 
CYP3A4.  An in vitro  transporter interaction assay showed that ARD -101 is a substrate of MDRI, 
MATE1, MATE2 -K, OAT3, and OCT2 transport ers. ARD -101 is an  in vitro  inhibitor of the 
MATE1, MATE2 -K, and OCT -2 transporters, with IC50 value s of 21.07, 57.11, and 9.47  μM, 
respectively.  
2.3.3.  Non-Clinical Safety Pharmacology and  Toxicology  
The toxicology program was designed to support clinical studi es in accordance with ICH Guidance 
M3(R2) . A non -GLP single dose acute toxicology study ( i.v. and p.o.) and a p ivotal GLP compliant 
general toxicology stud y with a  28-day treatment  (i.g.) and a  14-day recovery period have been 
conducted in Cynomolgus monkeys. In vitro  studies including bacterial reverse mutation assay 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 25 of 66 09 May 2022 
 and mammalian cell chromosome aberration test ha ve been conducted to evaluate genotoxicity of 
ARD -101.  
ARD -101 showed inhibition  of hERG current with an IC 50 of 99.2 µM (38143 ng/mL) in vitro . 
Cardiovascular toxicity was observed in a single Cynomolgus monkey after i.v. administration of 
ARD -101 at 4.85 mg/kg  (in the single dose toxicology/PK study). The animal show ed repetitive 
arrhythmia  immediately following injection, the serum  concentration was 2270 ng/m L at the first 
sampling time point (15 mins post -dose) , and this adverse effect recovered by 8 hours post- dose. 
The tolerated dose for an i.v. route is 1.62 mg/kg with a system ic exposure of 1460  ng*h/mL  and 
a peak serum concentration  (Cmax) of 803 ng/mL .  
In the 28 -day toxicity study in Cynomolgus monkeys, 100  mg/kg b.i.d.  i.g. administration of 
ARD -101 (human equivalent dose is 64.5 mg/kg , b.i.d. ) was well-tolerated in all animals , which 
is 37.33 -fold of the proposed starting dose in a first-in-human  (FIH) clinical study  (40 mg b.i.d for 
a 70 kg adult ). There was no mortality or moribundity found in ARD -101-treated  animals . ARD -
101 showed no local toxicity in the GI organs (stomach, duodenum, ileum, jejunum, cecum, colon, 
and rectum) based on gross pathology and histological microscopic examinations . Only transient 
decreases in body weights in animals administered with 100 mg/kg  dose were observed, which 
may be related to the pharmacological effect of ARD -101. The no -observed -adverse -effect level 
(NOAEL) was considered to be 100  mg/kg/dose  (200 mg/kg/day)  with a systemic exposure 
AUC 0-24h of 1210  ng*mL/h and 1400 ng*mL/h for female and male monkeys , respectively . 
ARD -101 did not show mutagenic  activity in the bacterial reverse mutation assay. The in vitro  
chromosomal aberration assay showed that ARD -101 was considered  negative for inducing 
structural aberrations of human peripheral blood lymphocytes ( HPBL)  in the 3 -h treatment with 
metabolic activation and the 22 -hour treatment without activation. ARD -101 was positive for 
inducing structural aberrations of HPBL  in the 3 -hour treatment without metabolic activation . No 
precipitate , pH changes or cytotoxicity was observed at any dose level during the study.  
Further details can be found in the Investigator’s Brochure.  
2.4. Summary of Findings from Previous Clinical Studies  
A FIH clinical study with the study drug  has been performed in healthy volunteers to interrogate 
safety and pharmacokinetics of multiple dose levels . 
The study consisted of 2 parts: A single ascending dose  part (SAD) and a multiple ascending dose 
part (MAD) , dosing subjects for 14 days BID. Each part tested three dose levels (40 mg, 100  mg 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 26 of 66 09 May 2022 
 and 240  mg) consecutively  in a randomized, double -blinded manner.  Forty -three  subjects were 
dosed in total , 23 females and 20 males , of which 31 received  ARD -101. 
The results are summarized below : 
2.4.1.  Overview of Clinical Pharmacology  
2.4.1.1.  Single Ascending Dose  
The SAD study evaluated PK parameters following administration of a single oral dose of ARD -
101 at 40 mg, 100 mg, or 240 mg in healthy adult subjects. Eligible subjects were 18 -55 years of 
age, with a body mass index between 18 -30 kg /m2 and a minimum weight of 50 kg. Subjects were 
orally dosed in 3 escalating cohorts of 40, 100, and 240 mg of ARD -101 or matching placebo 
capsules. For each dose cohort, 6 subjects received ARD -101 and 2 subjects received placebo. The 
study medication wa s administered to eligible subjects after a minimum of 8 h of fasting.  
Group  PK analyses have been conducted for all dose cohorts in Part 1 of the study. PK parameters 
for all doses are presented in Table 4 . Based on the area under the curves (AUCs) and maximum 
serum concentration (C max) between -subject variability (Geometric CV%) was high, ranging from 
45.8 to 53.7%. CV% for t1/2 values increased with i ncreases in ARD -101 dose level.  
Table 4  Geometric Mean (%CV) PK Parameters of ARD -101 Following Single Oral 
Dose Administration of ARD -101 
Parameter  
(Units)  40 mg  100 mg  240 mg  
AUC last (h*ng/mL)  4.81 (281.4) 15.9 (61. 1) 53.1 (4 5.8) 
AUC inf (h*ng/mL)  12.4 (10 6.8) 17.5 (57. 6) 55.8 (45.2) 
Cmax (ng/mL)  0.999 (259 .4) 3.04 (76.2)  12.4 (53.7)  
tmaxa (h) 1.33 (0.667 – 4.00)  1.21 (0.667 – 2.00)  1.08 (0.667 – 1.33)  
t1/2 (h) 8.27 (14.4)  11.1 (3 9.0) 18.4 (39. 0)b 
CL/F (L/h)  3220 (10 6.8) 5710 (57. 6) 4300 (45. 2) 
Vz/F (L)  38400 (11 4.0) 91700 (30.1)  114000 (5 6.9) 
a Median (min -max) presented; b Half-life estimates were calculated over a period of less than 2 half -lives for 3 
subjects in the 240 mg dose group.  
Following administration of a single 240 mg ARD -101 dose, quantifiable concentrations for all 
subjects were observed at 48 hours post dos e, with 3 of 6 subjects having quantifiable 
concentrations at 72 hours post dose. There was a 2.4 -fold increase in dose level from 100 to 240 
mg ARD -101. This resulted in increases in C max, AUC last, and AUC inf (4.08 -, 3.34 -, and 3.18 -fold, 
respectively).  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 27 of 66 09 May 2022 
 The geometric mean and highest peak plasma concentrations (C max) following single oral 
administration at these doses were 0.999 and 9.59 ng/mL (40 mg), 3.04 and 10.4 ng/mL (100 mg), 
and 12.4 and 29.7 ng/mL (240 mg) respectively, which represented 0.12% and 1.20%, 0.380% and 
1.30%, and 1.55% and 3.71% of the PK stopping criteria (800 ng/mL) for this Phase I study.  
2.4.1.2.  Multiple Ascending Dose  
The MAD study evaluated  PK parameters following repeated administration to date of oral doses 
of ARD -101 at 40 mg,  100 mg and 240  mg BID, in healthy adult subjects. Eligible subjects were 
18-55 years of age, with a body mass index between 18 -30 kg/m2 and a minimum weight of 50 kg. 
Subjects were orally dosed BID, for 14 days, or matching placebo capsules.  4 subjects received 
ARD -101 and 2 subjects received placebo  in each dose level . From Day 1 to Day 14, the study 
medication was administered twice daily (every 12 h) with approximately 12 h between doses.  
PK results are listed in Table 5. 
The geometric mean (on Day 14) and highest individual systemic exposure (on Day 1), based on 
Cmax, represented 1.14% and 2.55% of PK stopping criteria, respectively, at the 240 mg BID dose 
level.  
Accumulation after BID dosing for 14 days was 1.20 -fold for C max and 1.6 8-fold for AUC tau at 240  
mg BID . Steady state appears to have been reached by Day 11  at all tested  dose levels .  
  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 28 of 66 09 May 2022 
 Table 5  Geometric mean (%CV) PK parameters of ARD -101 BID oral dose 
administration of ARD -101 for 14 days  
Parameter (Units)  40 mg BID  100 mg BID  240 mg BID  
Day 1  Day 14  Day 1  Day 14  Day 1  Day 14  
AUC tau (h*ng/mL)  2.31 (187.9)  5.51 (83.5)  8.48 (63.0)  16.4 (55.3)  27.6 (80.3)  46.3 (46.7)  
DAUC tau (h*ng/mL/mg)  0.0577  
(187.9)  0.138  
(83.5)  0.0848  
(63.0)  0.164  
(55.3)  0.115  
(80.3)  0.193  
(46.7)  
Cmax (ng/mL)  0.584 (235.9)  1.27 (141.3)  1.85 (85.9)  3.02 (86.1)  7.64 (135.9)  9.13 (59.6)  
DC max (ng/mL/mg)  0.0146 
(235.9)  0.0317  
(141.3)  0.0185  
(85.9)  0.0302  
(86.1)  0.0318  
(135.9)  0.0380  
(59.6)  
tmaxa (h) 1.50  
(0.50 – 4.00)  1.75 
(1.08 – 4.00)  1.50 
(1.08 – 2.00)  1.08 
(0.50 – 4.00)  1.75 
(1.15 – 3.00)  1.08 
(0.50 – 2.00)  
Ctrough (ng/mL)  NC 0.147 (51.5)  0.183 (69.3)  0.481 (37.9)  0.415 (76.0)  1.21 (25.8)  
Cmin (ng/mL)  NA 0.119 (33.9)  NA 0.419 (25.1)  NA 1.21 (26.1)  
Cavg (ng/mL)  NA 0.459 (83.5)  NA 1.37 (55.3)  NA 3.86 (46.7)  
CL ss/F (L/h)  NA 7260 (83.5)  NA 6090 (55.3)  NA 5180 (46.7)  
Racc, Cmax NA 2.17 (495.5)  NA 1.66 (129.3)  NA 1.20 (50.1)  
Racc, AUC tau NA 2.39 (69.2)  NA 2.02 (61.5)  NA 1.68 (26.9)  
Racc, Ctrough NA 2.04 (21.5)  NA 2.89 (51.9)  NA 2.91 (45.9)  
a Median (min -max) presented ; NC, not calculated  
 
2.4.2.  Overview of Clinical Efficacy  
At the time of  the submission of this IND, no clinical study has been conducted to investigate the 
efficacy of ARD -101. 
2.4.3.  Overview of Clinical Safety  
Clinical safety is based on , three dose cohorts of the SAD part and three  dose cohort s of the 
MAD part .  
In the SAD part of the study, ARD -101 was well -tolerated by subjects after single administration 
of the three assigned doses (40, 100, and 240 mg). No adverse effects (AEs) were reported for any 
subject in the three dosing cohorts.  
ARD -101 was also well -tolerated by subjects for 14-day repeated administration at 40 mg , 100 mg 
and 240 mg  BID. Treatment -emergent  AEs that were judged as treatment related  by the 
investigator were rest ricted to Grade 1  or 2, and  were exper ienced by a total of 6 subjects  out of 
13 dosed with ARD -101 (46.2%) (Table 6). These consist ed of  gastrointestinal  disorder s (3 cases), 
nervous system  disorders (3 cases), skin and subcutaneous disorders (2 cases), and cardiac 
disorders (1 case) ( Table 7). Two cases  of skin restricted hypersensitivity  (urticaria)  occurred  at 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 29 of 66 09 May 2022 
 100 mg BID and 240 mg BID, respectively . The latter hypersensitivity was successfully addressed 
with premedication of oral antihistamine dosing as per protocol ; while the subject experiencing  
Grade 1 hypersensitivity  at the intermediate 100 mg BID dose was discontinued based on 
investigator’s decision and replaced . Gastrointest inal symptoms usually occurred, if so, early on 
and were self -limiting.  One case of palpitations was reported  lasting  for about 3h. An EC G 
performed during that episode showed normal sinus rhythm at 83 bpm with no changes from 
baseline . 
Table 6 Summary of Treatment -emergent Adverse Events - MAD Part  
 
   Placebo (BID)  
(N = 6)  
nS (%) [nE]  40 mg ARD -101 
(BID)  
(N = 4)  
nS (%) [nE]  100 mg ARD -101 
(BID)  
(N = 5)  
nS (%) [nE]  240 mg ARD -101 
(BID)  
(N = 4)  
nS (%) [nE]  Overall  
(N = 19)  
nS (%) [nE] 
 
TEAEs  
Overall  3 (50.0%) [5]  1 (25.0%) [5]  3 (60.0%) [5]  3 (75.0%) [6]  10 (52.6%) [21]  
Serious  --- --- --- --- --- 
Leading to Discontinuation  --- --- 1 (20.0%) [1]  --- 1 (5.3%) [1]  
Leading to Death  --- --- --- --- --- 
Severity  --- --- --- --- --- 
Grade 1  3 (50.0%) [5]  1 (25.0%) [5]  2 (40.0%) [3]  2 (50.0%) [5]  8 (42.1%) [18]  
Grade 2  --- --- 2 (40.0%) [2]  1 (25.0%) [1]  3 (15.8%) [3]  
Grade 3  --- --- --- --- --- 
Grade 4  --- --- --- --- --- 
 
Treatment -related  TEAEs  
Overall  1 (16.7%) [2]  1 (25.0%) [4]  2 (40.0%) [4]  3 (75.0%) [6]  7 (36.8%) [16]  
Serious  --- --- --- --- --- 
Leading to Discontinuation  --- --- 1 (20.0%) [1]  --- 1 (5.3%) [1]  
Leading to Death  --- --- --- --- --- 
Severity  --- --- --- --- --- 
Grade 1  1 (16.7%) [2]  1 (25.0%) [4]  1 (20.0%) [2]  2 (50.0%) [5]  5 (26.3%) [13]  
Grade 2  --- --- 2 (40.0%) [2]  1 (25.0%) [1]  3 (15.8%) [3]  
Grade 3  --- --- --- --- --- 
Grade 4  --- --- --- --- --- 
 
BID = twice  daily;  nE = number  of adverse  events;  nS = number  of subjects  with an adverse  event;  N = number  of subjects;  % = percentage  of su
bjects  with an adverse  event  (nS/N×100)  
Severity  grades:  1 = mild;  2 = moderate;  3 = severe;  4 = potentially  life-threatening  
Adverse  events  were  assigned  severity  grade  using  the Toxicity  Grading  Scale  for Healthy  Adult  and Adolescent  Volunteers  Enrolled  in Preventi
ve Vaccine  Clinical  Trials  Version  September  2007.  
A treatment -
emergent  adverse  event  (TEAE)  was defined  as an adverse  event  that started  during  or after the first dose,  or started  prior  to the first dose and incr
eased  in severity  after the first dose.  
A treatment -related  TEAE  was defined  as a TEAE  with a relationship  of related  to the study  treatment,  as determined  by the investigator.  
Where  a subject  experienced  multiple  TEAEs  with the same  preferred  term for the same  treatment,  this was counted  as 1 TEAE  for that treatment
 under  the maximum  severity  recorded.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 30 of 66 09 May 2022 
 Table 7 Summary of Treatment -related Treatment -emergent Adverse Evens by 
System Organ Class and Preferred Term - MAD Part  
 
2.4.4.  Benefits and Risks Conclusions  
According to our nonclinical studies, clinical data, and reported clinical studies on denatonium 
benzoate, ARD -101 has  demonstrated a well -tolerated safety profile and potential clinical benefit 
in the treatment of obesity. This safety profile supports the use of the dose and dosing regimen to 
be used in the Phase 2 trial in overweight patients . 
 
 System Organ Class  
  Preferred Term  Placebo (BID)  
(N = 6)  
nS (%)  40 mg ARD -101 
(BID)  
(N = 4)  
nS (%)  100 mg ARD -101 
(BID)  
(N = 5)  
nS (%)  240 mg ARD -101 
(BID)  
(N = 4)  
nS (%)  Overall  
(N = 19)  
nS (%)  
 
Overall  1 (16.7%)  1 (25.0%)  2 (40.0%)  3 (75.0%)  7 (36.8%)  
 
Gastrointestinal disorders  1 (16.7%)  1 (25.0%)  1 (20.0%)  1 (25.0%)  4 (21.1%)  
  Diarrhoea  --- --- 1 (20.0%)  1 (25.0%)  2 (10.5%)  
  Dyspepsia  --- 1 (25.0%)  --- 1 (25.0%)  2 (10.5%)  
  Nausea  --- 1 (25.0%)  1 (20.0%)  --- 2 (10.5%)  
  Abdominal distension  --- 1 (25.0%)  --- --- 1 (5.3%)  
  Abdominal pain  --- --- 1 (20.0%)  --- 1 (5.3%)  
  Flatulence  1 (16.7%)  --- --- --- 1 (5.3%)  
 
Nervous system disorders  1 (16.7%)  1 (25.0%)  --- 2 (50.0%)  4 (21.1%)  
  Headache  1 (16.7%)  1 (25.0%)  --- --- 2 (10.5%)  
  Dizziness  --- --- --- 1 (25.0%)  1 (5.3%)  
  Dysgeusia  --- --- --- 1 (25.0%)  1 (5.3%)  
 
Skin and subcutaneous tissue 
disorders  --- --- 1 (20.0%)  1 (25.0%)  2 (10.5%)  
  Urticaria  --- --- 1 (20.0%)  1 (25.0%)  2 (10.5%)  
 
Cardiac disorders  --- --- --- 1 (25.0%)  1 (5.3%)  
  Palpitations  --- --- --- 1 (25.0%)  1 (5.3%)  
 
BID = twice  daily;  nS = number  of subjects  with an adverse  event;  N = number  of subjects;  % = percentage  of subjects  with an adverse  event  (nS/
N×100)  
Adverse  events  were  coded  using  the Medical  Dictionary  for Regulatory  Activities  (MedDRA)  Version  23.0.  
A treatment -
emergent  adverse  event  (TEAE)  was defined  as an adverse  event  that started  during  or after the first dose,  or started  prior  to the first dose and incr
eased  in severity  after the first dose.  
A treatment -related  TEAE  was defined  as a TEAE  with a relationship  of related  to the study  treatment,  as determined  by the investigator.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 31 of 66 09 May 2022 
 3. STUDY ENDPOINTS  
3.1. Primary Endpoint  
• The percent total weight change at the end of treatment from baseline  
3.2. Secondary Endpoints  
• Safety and tolerability of ARD -101 by assessment of the incidence of TEAE  
• The change in blood lipid concentrations (total cholesterol, triglyceride, high density 
lipoprotein cholesterol, and low -density lipoprotein cholesterol) at the end of treatment 
from the baseline  
• The change in waist circumference at the end of treatment from the baseline  
• The change in HbA1c at the end of treatment from the baseline  
3.3. Exploratory Endpoints  
• Categorical weight loss. Proportion of subjects who lose < 5%  and ≥  5% of initial 
weight  
• Fasting circulating levels of GLP -1 (total and active), CCK, PYY, amylin, GIP (total 
and active), ghrelin, leptin, and adiponectin before the first dos ing, and at 1h and 2h 
after the first dos ing on day 1  
• Changes in response to MMTT, including:  
▪ Serum levels of glucose, insulin, and C -peptide prior to (negative timepoints) 
and post (positive timepoints) the Ensure meal given for MMTT  at baseline 
(run-in visit) and on day 28  
▪ Serum  level of FFA prior to (negative timepoints) and post (positive timepoints) 
the Ensure meal given for MMTT at baseline (run -in visit)  and on day 28  
▪ Circulating level of GLP -1 (total and active), CCK, PYY, amylin, GIP (total 
and ac tive), glucagon, and ghrelin prior to (negative timepoints) and post 
(positive timepoints) the Ensure meal given for MMTT at baseline (run -in visit) 
and on day 28  
▪ Circulating  cytokines and inflammatory markers such as CRP  at run in visit  and 
end of treatme nt (day 28)  performed during the MMTT  
▪ Circulating levels of bile acids, ferritin, leptin, and adiponectin at run in visit 
and end of treatment (day 28) performed during the MMTT  
• Body composition as measured by bioelectrical impedance scale  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 32 of 66 09 May 2022 
 • Body composition and hepatic steatosis by MRI PDFF + full body composition scan 
at pretreatment and end of treatment  
• The change in HOMA -IR at the end of treatment from the baseline   
• The change in fasting blood glucose at the end of treatment from the baseline   
• Hunger and control of eating as measured by Likert and visual analogue scales , 
respectively  
• Change in indirect calorimetry  
• The fecal samples will be collected during the run -in visit and on day 28 for 
microbiome analysis  to evaluate potential effects of the study medication  on fecal 
microbiome profile (optional for subjects)  
• Phenotypic  bitter  taste test (using commercially available test strips/kits) during the 
run-in visit of the study (optional for subjects)  
Already collected blood and fecal samples may also be stored and used for possible retrospective 
exploratory analysis which may include, but will not be limited to, understanding mechanisms of 
response to treatment (where r esponse is defined broadly to include biomarker change, tolerability 
or safety) and identification of other mechanisms of therapy.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 33 of 66 09 May 2022 
 4. STUDY DESIGN  
4.1. Overview  
This is a Phase 2, randomized, placebo -controlled  study of ARD -101 in subjects a BMI of 3 0-45 
kg/m2. 
This study has a planned enrollment of 30 subjects and will be conducted in a single center in the 
United States  
The s tudy will consist of a Screening Period (up to 28 days),  a Run -in Visite Period (up to  14 
days), a Treatment Period  (28 days) , and a Follow -up Period ( EOS Visit  within 14 days  after 
receiving the last dose of  ARD -101). The screening pro cedures will be initiate d upon completion 
of the informed consent process. Following completion of screeni ng procedures  and confirmation 
of eligibility, subjects will be enrolled to receive ARD -101.  
ARD -101 will be administered orally under fasting conditions (approximately 60 minutes  before 
breakfast and approximately 60 minutes  before  dinner ) at 200 mg BID for 28 days. Subjects will 
receive treatment in an outpatient setting and will be instructed to visit the clinical center 
periodically as scheduled in Table 1 for safety and efficacy assessments. The treatment may be 
discontinued due to intolerable toxicity, withdrawal of informed consent, discretion of principal 
investigator or end of the study.  
4.2. Justification  for Dose  
The dose of 200 mg BID was ch osen based on the available nonclinical studies  and clinical data . 
As described above, this dose has been found safe in the first -in-human trial and the 
pharmacokinetics support the prescribed dose level and duration.  
4.3. Study Duration  
The duration of participation for each subject will be up to approximately 84 days (12 weeks ). 
• Screening Period: Up to 28 days (4 weeks)  
• Run-in Visit: Up to 14 days (2 weeks)  
• Treatment Period: 28 days on ARD -101 (4 weeks)  
• Follow -up Period : 14 days (2 weeks). The EOS Visit  will occur  within  14 days after 
receiving the dose of ARD -101 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 34 of 66 09 May 2022 
 4.4. Study Completion  
For the entire study, study completion is defined as the last visit of the last subject for any protocol 
related activity (last subject, last visit). For individual subjects, study completion is defined as the 
time of the subject’s last data collection.  
4.5. Early Termination  
If a subject withdraws prematurely after dosing, all data normally collected should be collected at 
the time of premature  discontinuation. If deemed necessary by the Principal Investigator, the 
subject will be asked to return at the regularly scheduled EOS Visit.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 35 of 66 09 May 2022 
 5. STUDY POPULATION  
The study population will consist of male and female  obese  subjects with a BMI of 30 -45 kg/m2. 
5.1. Number of Subjects  
A total of approximately 30 subjects will be enrolled in the clinical study , randomized 2:1 against 
placebo .  
If any assessments for inclusion or exclusion criteria are out of permissible ranges during the 
Screening Period , repeat assessm ents may be allowed for those subjects at Principal Investigator ’s 
discretion.  
5.2. Inclusion Criteria  
Subjects must meet all the following criteria to be eligible for participation in this study:  
1. Male  and female subjects, 18 -75 years of age  
2. Willing and able to provide signed and dated informed consent prior to any study -related 
procedures and willing and able to comply with all study procedures  
3. BMI of 30 -45 kg/m2 
4. Stable body weight by subject report (± 5%) in the previous 6 months prior to randomization  
5. No abnormal findings or abnormalities of clinical significance in vital signs, physical 
examination, clinical laboratory tests (CBC, urinalysis, blood biochemistry, coagulation, 
pregnancy test (females of childbearing  potential), urine drug test, nicotine test, etc.), 12 -lead 
ECG during the Screening Period.  
6. Serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine 
aminotransferase) and total bilirubin (unless the subject has documented Gilbert syndrome) 
not exceeding 1.5-fold the upper laboratory norm  and eGFR >30 m L/min 
7. Standard 12 -lead ECG parameters after 10minutes resting in supine position in the following 
ranges;  120 ms <PR <220 ms, QRS <120 ms, QTc <=430 ms if male, <=450 ms if female and 
normal ECG tracing unless the Investigator considers an ECG abnormality within described 
limits to be not clinically relevant  
8. Stable or well controlled blood pressure per Invest igator’ s judgement during the Screening 
Period. Specifically: Vital signs after 10 minutes sitting in a chair (feet on floor, back 
supported):  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 36 of 66 09 May 2022 
 i. 95 mmHg < SBP <160 mmHg,  
ii. 45 mmHg <  DBP <100 mm Hg,  
iii. 40 bpm <  HR <100 bpm  
9. Prediabetes - defined as a fas ting blood glucose between 100 -125 mg/d L OR an HbA1c 
between 5.7 -6.5% at screening  
10. Type 2 diabetes - Defined as previous diagnosis by a healthcare professional OR a fasting blood 
glucose > 126 mg/d L OR HbA1c > 6.5% at screening.   
11. Patients with type 2 diabe tes treated with metformin may be enrolled.  However, patients with 
type 2 diabetes on any other therapy will be excluded.   
12. Female subjects must have negative pregnancy test and must not be lactating. For females able 
to bear children, a hormonal (i.e., or al, implantable, or injectable) and single barrier method 
(i.e., sponge), or a double -barrier method of birth control (i.e., condom with spermicide) or 
abstinence must be used/practiced throughout the study and for 90 days following last dose of 
study medi cation; for effective form of birth control.  
13. Females of non -childbearing potential, defined as surgically sterile (status post hysterectomy, 
bilateral oophorectomy, bilateral tubal ligation, bilateral salpingectomy, or bilateral tubal 
occlusion) or post -menopausal for at least 12 months (may be confirmed with a screening FSH 
level in the post -menopausal lab range), do not require contraception during the study.  
14. Males with female partners of childbearing potential must agree to a double -barrier method if 
they become sexually active during the study and for 90 days following the last dose of the 
study medication. Male subjects must not donate sperm for 90 days following their 
participation in the study.  
5.3. Exclusion Criteria  
Subjects who meet any of the following  criteria will be excluded from study participation:  
1. History of significant drug hypersensitivity or anaphylaxis  
2. Prior bariatric or GI surgery (excluding cholecystectomy, hysterectomy or appendectomy)  
3. Participation in a weight loss program or clinical tria l for weight loss within 30 days  prior to 
randomization  
4. Diabetes treatment (unless metformin as outlined), or chronic oral steroids, or treatment with 
immune modulators, anti -obesity drugs, chronic opiate therapy, or antipsychotic medications .   
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 37 of 66 09 May 2022 
 5. Received a ny experimental drugs or devices or have participated in a clinical study within 30 
days prior to randomization  
6. Currently receiving any drug -based therapy for weight management  
7. TSH level is outside of normal limit  
8. The presence of diseases with abnormal cl inical manifestations that need to be excluded based 
on their possible contribution to weight loss or weight gain, including but not limited to 
nervous, cardiovascular, blood and lymphatic system, immune, renal, hepatic, gastrointestinal, 
respiratory, meta bolic and skeletal diseases  
9. History of myocardial infarction, unstable angina, arterial revascularization, stroke, New York 
Heart Association Functional Class II -IV heart failure, or transient ischemic attack within 6 
months prior to Visit 1  
10. Any malignancy not considered cured (except focal, treated basal cell carcinoma and squamous 
cell carcinoma of the skin); a participant is considered cured if there has been no evidence of 
cancer recurrence in the previous 5 years  
11. History of major depressive d isorder or history of other severe psychiatric disorders (e.g., 
schizophrenia or bipolar disorder) within the last 2 years.  
12. Major surgery within 3 months prior to randomization or planned surgery during the study  
13. Donated ≥200 mL of blood (blood components)  or had massive blood loss, received blood 
transfusion or blood products within 3 months prior to randomization  
14. Planned sperm/egg donation within 6 months post randomization  
15. Positive urine drug test for any illicit non -prescription substances  
16. History of co nsuming more than 14 units of alcoholic beverages per week or of alcoholism or 
drug/chemical/substance abuse within past 2 years prior to enrollment (Note: one unit = 12 
ounces of beer, 4 ounces of wine or 1 ounce of spirits)  
17. Smoking any amount within 3 mo nths prior to randomization  
18. Excessive  consumption of  tea, coffee , and/or caffeinated beverages (more than 8 cups, 250 m L 
for each cup) every day within 3 months prior to enrollment  
19. Symptomatic viral, bacterial (including upper respiratory infection), or fungal (non -cutaneous) 
infection within 1 week prior to randomization  
20. History of human immunodeficiency virus antibody or active hepatitis  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 38 of 66 09 May 2022 
 21. A history of psychiatric and psychological condition that, in the judgment of the investigator, 
may i nterfere with the planned treatment and follow -up, affect subject compliance or place the 
subject at high risk from treatment -related complications  
22. Poor venous access or inability to tolerate venipuncture  
23. Any condition  or active drug treatment  that the inv estigator or primary physician believes may 
not be appropriate for participating  in the study  
5.4. Restrictions  
5.4.1.  Dietary and Fluid Restrictions  
Caffeine  
Subjects should not consume caffeine containing beverages exceeding 500  mg caffeine per day 
(5 cups of coffee ) during the study.  
Alcohol  
Subjects should not consume more than 3 units (males) or 2 units (females) per day during the 
study (1 unit is equal to approximately ½ pint [284 mL] of beer, one small glass [125  mL] of wine, 
or one measure [25 mL] of spirits).  
5.4.2.  Lifestyle Considerations  
Drugs of abuse  
Subjects must refrain from use of recreational drugs  including THC containing products  for the 
duration of the study.  
Nicotine  
No smoking or use of other nicotine -containing products (snuff, chewing tobacco, cigars, pipes or 
nicotine -replacement products such as nicotine chewing gum and nicotine plasters) will be allowed  
during the study . 
 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 39 of 66 09 May 2022 
 6. INVESTIGATIONAL MEDICINAL PRODUCT  
6.1. Premedi cation  
No pre -medication is required prior to administration of study medication . For subjects who 
experience Grade  2 acute allergic reactions and are able to continue on the treatment, 
premedication with an H1 antihistamine should be given.  
6.2. Identity of th e Investigational Medicinal Products  
ARD -101 drug product is an encapsulated oral formulation of denatonium acetate monohydrate. 
The ARD -101 and placebo drug product will be supplied as white opaque body and white opaque 
cap hard gelatin capsules. The ARD -101 drug product contains 23.61 mg  or 59.03 mg  of 
denatonium acetate monohydrate (equivalent as 20 mg  or 50 mg  of denatonium base) together 
with povidone, sugar spheres, hypromellose, and talc as inactive ingredients. The inner content of 
the placebo has t he same weight as the inner content of ARD -101 drug product, but only contains 
sugar spheres (no active ingredient).  
6.3. Supply, Packaging, Labeling and Storage  
Study drug and matching placebo will be supplied by Sponsor . The study medication  will be 
packaged and labeled according to applicable local and regulatory requirements.  
All supplies of study medication  must be stored in accordance with the manufacturer’s 
instructions . The ARD -101 will be stored at room temperature in a securely locked area, accessible 
to authorized persons only , until dispensation . 
Further details will be  provided in the Pharmacy Manual.  
6.4. Drug Accountability, Dispensing and Destruction  
The Principal Investigator  or designee is responsible for maintaining accurate accountabilit y 
records of the study drug throughout the clinical study. Products returned will be stored under the 
same conditions as products not yet dispensed.  
All dispensing and accountability records will be available for Sponsor review. The Study Monitor 
will perform drug accountability at regular intervals.  
Study medication  will be dispensed for each subject according to the protocol  and Pharmacy 
Manual . 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 40 of 66 09 May 2022 
 After receiving Sponsor approval in writing, all unused or partially used study medication  will be 
returned to the Sponsor or designated third party or for preparing the study medication  for 
destruction via incineration.  
6.5. Dose Modification  
The dose level may not be reduced. If any ≥ Grade 3 toxicities or any intolerable Grade 2 toxicity 
occurs, treatment should b e discontinued permanently. Intolerable toxicity is defined as, in the 
opinion of Principal I nvestigator and Medical Monitor, any toxicity that poses a significant health 
risk to the subject. Treatment may continue on any Grade 1 toxic reactions or Grade 2 anorexia or 
Grade 2 weight loss. For any other Grade 2 toxicities, dosing may be interrupted for up to 3  days 
and may  be resumed at the medical judg ment  of Investigator once the toxicity has resolved to 
Grade 0 -1. A missed dose should not be made up. In the event of multiple toxicities, dosing 
management should be based on the worst toxicity observed. Subjects will be in structed to notify 
Investigators at the first occurrence of any adverse symptom.  
6.6. Stopping Rules  
At any time during the study, the subject must discontinue study drug treatment, if one of the 
following events occur:  
 
• An increase of AST and/or ALT (> 3x ULN) are observed in the presence of 
increased (> 2x ULN) alkaline phosphatase and/or total bilirubin.  
• A sustained AST or ALT increase, defined as three consecutive values of AST 
and/or ALT greater than 5x ULN within a period of 14 days.  
• A treatment -related Grade 3 or greater adverse event (other than AST or ALT 
increase as described above) is noted by the Investigator.  
• A relevant decrease of eGFR as per investigator  
  
If any of the above stopping rules are met the fol lowing action(s) should be taken:  
 
1. Stop dosing and convene a Safety Review Committee meeting;  
2. Review AE for evidence of relationship to treatment;   
3. May resume enrollment and continue the study if recommended by the Safety Review 
Committee.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 41 of 66 09 May 2022 
 6.7. Subject Identification  
6.7.1.  Screening Numbers  
All screened subjects are assigned a unique screening number. The screening numbers are numbers 
that identify subjects from time of screening until time of enrollment .  
6.7.2.  Enrollment  Numbers  
Eligible s ubjects will be assigned a n enrollment  number. The enrollment number  will include 6-
digit site number and subject numbers starting with 101  as below .  
• Subject 100 -101 
Once a n enrollment  number has been allocated to one subject, it may not be assigned to another 
subject.  
6.8. Compliance  
Dosing will be performed by trained, qualified personnel designated by the Principal Investigator .  
6.9. Special Precautions and Management of AEs  
6.9.1.  Eating disorders  
ARD -101 may decrease appetite and subsequently change a subject’s eating behavior by delaying 
gastric empty ing and inducing the glucagon -like peptide -1 and cholecystokinin  secretion into the 
circulation that targets the central nervous system ( CNS ) to cause satiety/hunger sensation. 
Subjects who develop any eating disorders during study treatment should be permanently 
discontinued from study drug.  
6.9.2.  Allergic reactions  
One case of allergic reaction has been reported in a female subject receiving denato nium benzoate , 
a compound in the same class as ARD -101 (Deloose E et al. 2017 ). Drug all ergic reactions can be 
either acute or delayed. The acute allergic reactions that usually occur within 1  h after drug 
exposure are typically IgE mediated while those that usually occur 2  to 6 h after drug exposure 
have more complicated pathophysiological m echanisms. Subjects with a localized Grade 2 acute 
allergic reaction might continue on the treatment with premedication of H1 antihistamine. Subjects 
with recurrent Grade  2 acute allergic reactions with premedication, Grade 2 delayed allergic 
reactions, or  Grade 3 to 4 acute allergic reactions should permanently discontinue the study drug.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 42 of 66 09 May 2022 
 6.9.3.  Management of gastrointestinal disorders  
Early recognition and management of potential GI disorders may mitigate more severe and 
subsequent toxicities.  
6.9.4.  Embryo -fetal Tox icity 
The effect of ARD -101 on embryo -fetal development has not been tested. Thus, a highly effective 
form of contraception must be used, and enrolled subjects should receive instructions regarding 
this during the entire study from enrollment  to 90 days af ter last dose administration.  
6.10. Concomitant Therapy  
Any medicinal product, prescribed or OTC,  including vitamins, natural , and herbal remedies, taken  
by a subject other than the study medication , is considered concomitant medication . 
Any concomitant treatment will be given only if deemed strictly necessary by the Principal 
Investigator or designee. Use of concomitant medication will be recorded and reported.  
Particularly , as described in Section 2.3.2 , ARD -101 is a substrate of the MDR1, MATE1, 
MATE2 -K, OAT3 and OCT2  transporters. Coadministration of these transporter inhibitors have 
the potential to  alter the pharmacokinetics of ARD -101. Therefore, before placing a  subject on a 
specific medication/therapy, it is the responsibility of the investigator to check  on potential drug -
drug interactions between that medication/therapy and  ARD -101 based on the Drug Development 
and Drug Interactions: Table of Substrates, Inhibitors and Inducers  
(https://www.fda.gov/drugs/drug -interactions -labeling/drug -development -and-drug-interactions -
table -substrates -inhibitors -and-inducers ), and Drug -Drug Interaction Database  
(https://www.fda.gov/drugs/drug -interactions -labeling/ databases ) of FDA. 
6.10.1.  Permitted Medications/Procedures  
Subjects are permitted to use medications consistent with those permitted , includ ing the use of 
contraceptive medications and hydrocortisone  cream.  All concomitant medications are subject to 
approval by t he principal investigator.  
No concomitant use  of approved obesity drugs or diabetes treatment (excluding metformin ), 
MDR1, MATE1, MATE2 -K, OAT3, or OCT2 inhibitors, or any drug deemed incompatible with 
trial participation as per investigator judgement .  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 43 of 66 09 May 2022 
 7. DISCONTINUATION  
7.1. Subject Withdrawal and Replacement  
Subject participation may be terminated prior to completing the study and the reason recorded as 
follows:  
  Adverse event  
  Protocol violation  
  Lost to follow -up 
  Subject withdrew consent at own request  
  Other  
A genuine effort must be made to determine the reason(s) why a subject fails to return for the 
necessary visits or is discontinued from the study. If the subject is unreachable by telephone, a 
registered letter, at the minimum, should be sent to the subject requesting him/her to contact the 
clinic.  
Withdrawn subjects may be replaced  until the full cohort has completed the study . 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 44 of 66 09 May 2022 
 8. STUDY ASSESSMENTS AND PROCEDURES  
For timing of assessments, refer to the Schedule of Assessments Table  1.  
8.1. Eligibility Screening  
All subjects must sign an informed consent form (ICF) prior to the conduct of any screening 
procedures. Screening assessments will occur within 28 days prior to the first dose of study 
medication . The subject’s relevant medical history and demographic data will be obtained. 
Retesting of abnormal screening va lues that lead to exclusion are allowed during the Screening 
Period (to reassess eligibility). The last result obtained prior to the first dose of study medication 
will be used to determine eligibility . 
8.2. Safety Variables  
8.2.1.  Adverse Events  
Adverse event reporti ng will begin for each subject from the date the ICF is signed  and will 
continue until the EOS  Visit . 
8.2.1.1.  Definitions  
8.2.1.1.1.  Definition of Adverse Event  
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical produ ct and which does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product.  
Other untoward events occurring in the framework of a clinical study will be recorded as AEs, e.g. 
those occurring during treatment -free periods (including screeni ng or post -treatment follow -up 
periods), in association with study -related procedures and assessments, or under placebo. For study 
medication , lack of efficacy may be an expected potential outcome and should not be reported as 
an AE unless the event is unu sual in some w ay, e.g., greater in severity.  
Concomitant illnesses, which existed prior to entry into the clinical study, will not be considered 
AEs unless they worsen during the Treatment Period. Pre-existing  conditions will be recorded as 
part of the sub ject’s medical history.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 45 of 66 09 May 2022 
 8.2.1.1.2.  Definition of Serious Adverse Event  
An SAE is defined as any untoward medical occurrence that at any dose:  
• Results in death  
• Is life -threatening; this means that the subject was at risk of death at the time of the event; it 
does not mean that the event hypothetically might have caused death if it were more severe  
• Requires inpatient hospitalization or prolongation in existing hospitalization  
• Results in persistent or significant disability/ incapacity or substantial disruption of the ability 
to conduct normal life functions  
• Is a congenital anomaly /birth defect, or  
• Is another important medical event (see below)  
Important medical events that do not result in death, are not life -threatening or do not require 
hospitalization may be considered SAEs when, based on appropriate medical judgment, they may 
jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed above.  Examples of such medical events include allergic bronchospasm requiri ng 
intensive treatment in an emergency room or in a physician’s office, blood dyscrasias or seizures 
that do not result in in -patient hospitalization, and the development of drug dependency or drug 
abuse.  
A distinction should be drawn between serious and s evere AEs. Severity is a measure of intensity 
whereas seriousness is defined by the criteria above. For example, a mild degree of gastrointestinal 
bleeding requiring an overnight hospitalization for monitoring purposes would be considered an 
SAE but  is not  necessarily severe. Similarly, an AE that is severe in intensity is not necessarily an 
SAE. For example, alopecia may be assessed as severe in intensity but would not be considered 
an SAE.  
Medical and scientific judgment should be exercised in deciding if  an AE is serious and if 
expedited reporting is appropriate.  
8.2.1.2.  Recording of Adverse Events  
Adverse events should be collected and recorded for each subject from the date the ICF is signed 
until the end of their participation in the study, i.e., the subject h as discontinued or completed the 
study.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 46 of 66 09 May 2022 
 Adverse events may be volunteered spontaneously by the subject, or discovered by study staff 
during physical examinations or by asking an open, non -leading question such as ‘How have you 
been feeling since you were l ast asked?’ All AEs and any required remedial action will be 
recorded. The nature of AE, date (and time, if known) of AE onset, date (and time, if known) of 
AE outcome to date, severity and action taken of the AE will be documented together with the 
Princi pal Investigator ’s assessment of the seriousness of the AE and causal relationship  to study 
drug and/or study procedure.  
All AEs should be recorded individually in the subject’s own words (verbatim) unless, in the 
opinion of the Principal Investigator , the AEs constitute components of a recognized condition, 
disease or syndrome. In the latter case, the condition, disease or syndrome should be named rather 
than each individual symptom. The AEs will subsequently be coded using the Medical Dictionary 
for Regul atory Activities (MedDRA).  Severity of AEs will be graded using the Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers  Enrolled in Preventive Vaccine Clinical Trials  
(September, 2007).  
8.2.1.3.  Assessment of Adverse Events  
Each AE will be assessed b y the Principal Investigator  as per  the categories discussed in the 
following sections . 
8.2.1.3.1.  Intensity  
The Principal Investigator  will assess all AEs for severity in accordance with the following 
standard ratings.  
• Mild  (Grade 1) : Ordinarily transient symptoms, does not influence performance of subject’s 
daily activities. Treatment is not ordinarily indicated.  
• Moderate  (Grade 2) : Marked symptoms, sufficient to make the subject uncomfortable. 
Moderate influence on performance of subject’s daily activities. Treatme nt may be necessary.  
• Severe  (Grade 3) : Symptoms cause considerable discomfort. Substantial influence on subject’s 
daily activities. May be unable to continue in the study and treatment may be necessary.  
• Potentially Life Threatening (Grade 4): Symptoms require emergency room (ER) visit or 
hospitalization.  
When changes in the intensity of an AE occur more frequently than once a day, the maximum 
intensity for the event should be noted for that day. Any change in severity of signs and symptoms 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 47 of 66 09 May 2022 
 over a number of days will be captured by recording a new AE, with the amended severity grade, 
and the date (and time, if known) of the change.  
8.2.1.3.2.  Causality  
The Principal Investigator  will assess the causality/relationship between the study medication  and 
the AE . The Principal  Investigator is responsible for assessing the relationship to study medication  
using clinical judgment and the following considerations : 
• No: Evidence exists that the AE has an etiology other than the study drug. For SAEs, an 
alternative causality  must be provided (e.g., pre -existing condition, concomitant 
medication)  
• Yes: There is reasonable possibility that the event may have been caused by the study 
medication . 
8.2.1.4.  Reporting of Serious Adverse Events  
The Principal Investigator  will review each SAE a nd evaluate the intensity and the causal 
relationship of the event to study drug. All SAEs will be recorded from signing of the IC F until 
the EOS  Visit. Serious AEs occurring after the EOS  Visit  and coming to the attention of the 
Principal Investigator  must be reported only if there is (in the opinion of the Principal Investigator ) 
reasonable causal relationship with the study drug.  
The Principal Investigator  is responsible for providing notification to Sponsor of any SAE, whether 
deemed study medication -related or not, that a subject experiences during their participation in 
study within 24  h of becoming aware of the event.  
Initial reports of SAEs must be followed later with detailed descriptions, including clear 
photocopies of other documents as necessary ( e.g., hospital reports, consultant reports, autopsy 
reports), with the subject’s personal identifiers removed.  
Information on SUSARs will be collected and reported to the regulatory authority and the IEC  as 
required per guidelines . 
If the SUSAR  is fatal or life -threatening, associated with the use of the study medication , and 
unexpected, the regulatory authority and the IEC will be notified per guidelines after being made 
aware of the case. Additional follow -up (cause of death, autopsy report, h ospital report) 
information should be reported per guidelines. SUSARs which are not fatal and not life -threatening 
are to be reported per guidelines.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 48 of 66 09 May 2022 
 The Sponsor will notify the Investigators of relevant information about SUSARs that could 
adversely affec t the safety of subjects in a timely fashion. Follow -up information may be submitted 
if necessary. The Sponsor will also provide annual safety reports for submission to the regulatory 
authority and the IEC responsible for the clinical study. These updates will include information on 
SUSARs and other relevant safety findings.  
8.2.1.5.  Follow -up of Adverse Events  
All AEs experienced by a subject, irrespective of the suspected causality, will be monitored until 
the event has resolved, until any abnormal laboratory valu es have returned to baseline or stabilized 
at a level acceptable to the Principal Investigator  and Medical Monitor, until there is a satisfactory 
explanation for the changes observed or until the subject is lost to follow -up. 
8.2.1.6.  Pregnancy  
The Sponsor has a re sponsibility to monitor the outcome of all pregnancies reported during the 
clinical study.  
Pregnancy alone is not regarded as an AE unless there is a suspicion that the study drug may have 
interfered with the effectiveness of a contraceptive medication. El ective abortions without 
complications should not be regarded as AEs, unless they were therapeutic abortions (see below). 
Hospitalization for normal delivery of a healthy newborn should not be considered an SAE.  
Each pregnancy must be reported by the Princ ipal Investigator  to the Sponsor within 2 days  after 
becoming aware of the pregnancy. The Principal Investigator  must follow -up and document the 
course and the outcome of all pregnancies even if the subject was withdrawn from the clinical 
study or if the c linical study has finished.  
All outcomes of pregnancy must be reported by the Principal Investigator  to the Sponsor on the 
pregnancy outcome report form within 2 days  after he/she has gained knowledge of the normal 
delivery or elective abortion.  
Any SAE th at occurs during pregnancy must be recorded on the SAE Report Form (e.g., maternal 
serious complications, therapeutic abortion, ectopic pregnancy, stillbirth, neonatal death, 
congenital anomaly, birth defect) and reported within 24  h in accordance with the  procedure for 
reporting SAEs.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 49 of 66 09 May 2022 
 8.2.2.  Clinical Laboratory Assessments  
Samples for clinical laboratory assessments will be collected at the time points detailed in the 
Schedule of Assessments ( Table 1). Samples will be collected in appropriate tubes and handled 
according to standard procedures of the applicable laboratory . 
Any value outside the normal range will be flagged for the attentio n of the Principal Investigator  
or designee at the site. The Principal Investigator  or designee will indicate whether  the value is of 
clinical significance. Additional testing during the study may be done if medically indicated. If a 
clinically significant  abnormality is found in the samples taken after dosing, during the study, 
and/or at the EOS  Visit, it should be recorded as an AE and the subject will be followed until the 
test(s) has ( have) normalized or stabilized , at the discretion of the Principal In vestigator . 
8.2.3.  Vital Signs  
Vital signs will be assessed at the time points detailed in the Schedule of Assessments Table  1. 
The following vital signs will  be measur ed: 
• Blood pressure (systolic and diastolic [mmHg])  
• Pulse  (bpm)  
• Body temperature (°C)  
• Respiratory rate (breaths per minute)  
8.2.4.  Standard 12 -lead Electrocardiograms  
Standard safety 12 -lead ECGs will be performed at the time points detailed in the Schedule of 
Assessments ( Table 1). 
The ECG will include all 12 standard leads.  
All ECGs must be evaluated by a qualified physician for the presence of abnormalities.  If a 
clinically significant abnormality is found, it should be recorded as an AE and the subject will be 
followed until the test(s) has (have) normalized or stabilized, at the discretion of the Principal 
Investigator . 
8.2.5.  Bioimpedance  
Body composition will be assessed via scale measuring bioimpedance at the time points detailed 
in the Schedule of Assessments ( Table 1). 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 50 of 66 09 May 2022 
 8.2.6.  MRI PDFF and Full Body Composition Scan  
In order to better assess overall body composition including quantification of lean body mass, liver 
fat content and other related parameters, MRI scan will be perform ed at the time points detailed at 
the time points detailed in the Schedule of Assessments ( Table 1). 
8.2.7.  Mixed Meal Tolerance Test (MMTT)  
The MMTT permits measurement of intestinal (incretin secretion), β-cell (insulin secretion), 
hepatic (insulin extraction), muscle, and adipose tissue respon ses to ingesting calories. The mixed 
meal, containing glucose, fat and protein (2x Ensure 8 oz. for a total of 16 oz., 66 grams 
carbohydrate ( CHO ), 440 calories), is more physiologic than the glucose only challenge in an oral 
glucose tolerance test (OGTT).  The MMTT will be performed at the time points detailed in the 
Schedule of Assessments ( Table 1) and as described in the Appendix .  
8.2.8.  Indirect Calorimetr y 
Continuous indirect calorimetry using a commercial instrument (Vmax Encore VS 29N, 
CareFusion, Yorba Linda, CA, USA) will be performed during basal and postprandial periods on 
the days when the MMTT are performed.   
At -80 and 195 minutes during the MMTT , the canopy will be placed over the subject’s head to 
collect data from 10 continuous minutes at steady -state (no longer than 30 minutes) during each 
interval for determination of the substrate oxidation rates at basal condition, and during the MMTT 
ass o utlined in the  Schedule of Assessments ( Table 1). 
8.2.9.  Physical Examinations  
Physical examinations will be performed at the time points detailed in the Schedule of Assessments 
(Table 1). 
Full physical examination:  
An assessment of general appearance and a review of systems (dermatologic, head, eyes, ears, 
nose, mouth/throat/neck, thyroid, lymph nodes, respiratory, cardiovascular, gastrointes tinal, 
extremities, musculoskeletal, neurologic and psychiatric systems).  
Brief physical examination:  
An assessment of the general appearance, skin, cardiovascular system, respiratory system and 
abdomen.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 51 of 66 09 May 2022 
 The brief physical examination may be extended to a full physical examination if considered 
necessary by the Principal Investigator. Other evaluations may be performed as deemed necessary 
by the Principal Investigator.  
8.2.10.  Continuous Glucose Monitoring  
Assessments  will be performed at the time points detailed in the Schedule of Assessments (Table 
1). 
Glucose levels will be monitored using the Continuous Glucose Monitoring  (CGM ) device. The 
CGM device will be used to track blood sugar levels day and night, and it will collect readings 
automatically every 5 minutes. The CGM sensor is a round disk with the circumference equal to 
that of a quarter, with the thickness of 2 quarters. It has a small filament that is inserted 
subcutaneously via a small needle that is then retracted and removed, leaving just the filament.  
The CGM sensor adheres to the skin leaving the filament in place for 14 days and stores the 
recorded glucose readings until downloaded by a study team member.   
During the Run -in Period, the CGM sensor will be applied to the sub ject and they will be required 
to wear it for a minimum duration of two weeks prior to Treatment Period Day 1. Data from the 
CGM will be downloaded and a report will be generated using the software  provided by the device . 
The report outlines typical measur es of glycemic control: mean glucose, standard deviation, time 
in range and daily patterns. In addition, a raw data file is available with each time point of 
collection and glucose reading.”   
8.2.11.  Circulating Hormones  
To investigate the effect of the study medication on circulating gut hormone levels, all subjects of 
the study will undergo  a fasting blood draw before the first dose, and 1h and 2h after the first dose 
on day 1  for measuring fasting c irculating levels of  the following gut hormnones:  GLP -1 (total and 
active),  CCK, PYY, amylin, GIP (total and active), ghrelin, leptin, and adiponectin  (Table 1). 
8.2.12.  Fecal Microbiome Analysis  
All subjects of t he study will optionally provide their fecal samples during the run -in visit and on 
day 28 for microbiome analysis to evaluate potential effects of the study medication  on fecal 
microbiome profile  (Table 1). 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 52 of 66 09 May 2022 
 8.2.13.  Non-invasive Phenotypic Bitter T aste Test 
All subjects of the study will optionally  undergo a non -invasive phenotypic bitter taste test using  
commercialized  phenylthiocarbamide  (PTC) and 6-n-propylthiouracil (PROP ) taste strips , and a 
commercialized Allegro Bitrex® Fit Test Kit  during the run -in visit of the study  (Table 1). This 
data can be used to retroactively assess a correlation of bitter taste sensitivity of subjects with the 
efficacy of the study medication . 
 
 
 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 53 of 66 09 May 2022 
 9. STATISTICAL CONSIDERATIONS  
9.1. Study Population  
9.1.1.  Protocol Deviations  
Important p rotocol deviati ons will be listed by subject.  
9.2. General Considerations  
Continuous data per treatment arm will be summarized using descriptive statistics (number, mean, 
standard deviation [SD], minimum, median and maximum). Categorical data will be  summarized 
using frequency tables (number and percentage).  
9.3. Subject Disposition  
Subjects excluded from the safety  analysis sets  will be listed including the reason for exclusion. 
Subject disposition will be summarized and will include the following informa tion: Number of 
subjects dosed , number and percentage of subjects completing the study and the number and 
percentage of subjects who were withdrawn (including reasons for withdrawal). Disposition data 
will be presented based on all.  
Subject discontinuation s will be listed including the date of study exit, duration of treatment and 
reason for discontinuation. A listing of informed consent response will also be presented.  
9.4. Demographic and Anthropometric Information and Baseline Characteristics  
Demographic and anthropometric variables (age, sex, ethnicity, race, height, body weight and 
BMI) will be listed by subject. Demographic characteristics (age, sex, ethnicity and race) and 
anthropometric characteristics (height, body weight , and BMI) will be summarized for  all subjects 
in the safety analysis set. The denominator for percentages will be the number of subjects in the 
safety analysis set for each treatment or for all subjects as applicable.  
Medical history data will be listed by subject including visit, descri ption of the disease/procedure, 
MedDRA system organ class (SOC ), MedDRA preferred term (PT), start date, and stop date (or 
ongoing if applicable).  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 54 of 66 09 May 2022 
 9.5. Prior and Concomitant Medication and Drug Administration  
Prior medications are those that started and stopped prior to the first dose of study medication . 
Concomitant medications are those taken after first dosing (including medications that started prior 
to dosing and continued after).  
Prior and concomitant med ication will be listed by subject and will include the following 
information: reported name, PT, the route of administration, dose, frequency, start date/time, 
duration and indication.  
Prior and concomitant medication will be coded according to the World Health Organization Drug 
Dictionary (WHO -DD) latest version.  
Drug administration dates and times will be listed for each subject.  
9.6. Exposure  
A listing of drug administration will be created and will include the date and time of administration.  
9.7. Safety A nalyses  
Where applicable, pre -dose measurements on Day 1 are considered baseline values for safety 
variables.  
9.7.1.  Adverse Events  
All AEs will be listed  and summarized per treatment arm . The number and percent of subjects 
experiencing an event will be tabulated  for each SOC  and PT. The AEs will also be tabulated 
according to intensity and causality.  A TEAE is defined as an AE with a start date on or after the 
first dose of study drug, or that worsened following first administration of study drug. For purposes 
of data analysis, the end of the TEAE period will be the last time point when a subject was 
evaluated for AEs.  
The AEs (TEAEs) will be tabulated according to intensity and causality, as applicable.  
Non-TEAEs will be listed, as applicable.  
Serious AEs will be  listed separately.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 55 of 66 09 May 2022 
 9.7.2.  Clinical Laboratory Tests  
Individual data listings of laboratory results will be presented for each subject. Flags will be 
attached to values outside of the laboratory’s reference limits along with the Principal 
Investigator ’s assessmen t or designee . Clinically significant laboratory test abnormalities that were 
considered AEs by the Principal Investigator  will be  presented in the AE listings.  
Clinical laboratory tests (observed values) will be summarized descriptively in tabular format. 
Shift tables will be presented for  select laboratory parameters.  
9.7.3.  Vital Signs  
Individual data listings of vital signs (observed and change from baseline) will be presented for 
each subject. Individual clinically significant vital sign s findings that  were considered AEs by the 
Principal Investigator  will be presented in the AE listings.  
Observed values as well as change from baseline data will be summarized d escriptively in tabular 
format.  
9.7.4.  Standard 12 -lead Electrocardiogram  
Standard 12 -lead ECG data ( observed and change from baseline) will be listed for each subject 
and time point. Observed values will be summarized descriptively in tabular format. Change from 
baseline will be summarized descriptively for QTc data. A categorical QTc analysis will also  be 
performed.  
9.7.5.  Physical Examination  
Abnormal physical examin ation findings will be listed.  
9.8. Exploratory analysis  
Exploratory analysis may be presented separately from the main clinical study report ( CSR ). 
Further details on exploratory analyses will be provi ded in the SAP . 
9.9. Determination of Sample Size  
The determination of sample size is not based on statistical considerations of power but 25 subjects 
is considered sufficient to meet the study objectives.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 56 of 66 09 May 2022 
 10. ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS  
10.1. Data Quality Assurance  
The Sponsor or designee will conduct a study initiation visit to verify the qualifications of the 
Principal Investigator , insp ect the facilities and inform the Principal Investigator  of responsibilities 
and procedures for ensuring adequate and correct documentation.  
The Principal Investigator  must prepare and maintain adequate and accurate records of all 
observations and other da ta pertinent to the clinical study for each study participant. Frequent 
communication between the clinical site and the Sponsor is essential to ensure that the safety of 
the study is monitored adequately. The Principal Investigator  will make all appropriat e safety 
assessments on an ongoing basis. The Medical Monitor may review safety information as it 
becomes available throughout the study.  
All aspects of the study will be carefully monitored with respect to Good Clinical Practice (GCP ) 
and SOPs for complia nce with applicable government regulations. The Study Monitor will be an 
authorized individual designated by the Sponsor. The Study Monitor will have access to all records 
necessary to ensure integrity of the data and will periodically review the prog ress of the study with 
the Principal Investigator . 
10.2. Data Collection and Access to Source Data/Documents  
The Principal  Investigator will ensure the accuracy, completeness and timeliness of the data 
reported to the Sponsor. The Investigator or designee will cooperate with the Sponsor’s 
representative(s) for the periodic review of study documents to ensure the accuracy and 
completeness of the data at each scheduled monitoring visit.  Data clarification requests will be 
provided to the study team by means of ele ctronic or manual queries.  
The Investigator will allow Sponsor representatives, contract designees, authorized regulatory 
authority inspectors and the IEC to have direct access to all electronic records pertaining to the 
study.  
All data should be recorded,  handled and stored in a way that allows its accurate reporting, 
interpretation and verification.  
10.3. Archiving Study Documents  
All source documents generated in connection with the study will be retained in the limited access 
file storage area, respecting the  privacy and confidentiality of all records that could identify the 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 57 of 66 09 May 2022 
 subjects. Direct access is allowed only for authori zed people for monitoring and auditing purposes. 
Source documents will be handled, stored and archived according to in -house procedures.  
The Investigator's Site File will be archived by the CRO for at least 2  years after completion of the 
study  or longer if agreed upon by the Sponsor . 
10.4. Good Clinical Practice  
The procedures set out in this clinical study protocol are designed to ensure that t he Sponsor and 
the Principal Investigator  abide by the principles of the ICH guidelines on GCP. The clinical study 
also will be carried out in keeping with national and local legal requirements (in accordance with 
United States investigational new drug [IN D] regulations [21  CFR  56]).  
10.5. Informed Consent  
Eligible subjects may only be included in the study after providing IRB/ IEC approved informed 
consent.  
Informed consent must be obtained from the subject before conducting any study -specific 
procedure.  
As part of the informed consent procedure, the Principal Investigator or designee must explain 
orally and in writing the nature, duration and purpose of the study and the action of the drug in 
such a manner that the subject is aware of the potential risks, inconve niences or AEs that may 
occur. The subject should be informed that he/she is free to withdraw from the study at any time. 
Subjects will receive all information that is required by federal regulations and ICH guidelines. 
The ICF must be signed and dated; on e copy will be handed to the subject, and the Principal 
Investigator will retain a copy as part of the clinical study records. The Principal Investigator will 
not undertake any investigation specifically required for the clinical study until written consen t 
has been obtained. The terms of the consent and when it was obtained must be documented in the 
subject source documents.  
The Sponsor will review the Investigator -proposed ICF to ensure it complies with the ICH GCP 
guideline (including the ethical princip les that have their origins in the Declaration of Helsinki) 
and regulatory requirements and is considered appropriate for this study. The Principal Investigator 
or designee will provide the Sponsor with a copy of the IRB/ IEC approved ICF prior to the start  
of the study.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 58 of 66 09 May 2022 
 If a protocol amendment is required, then the ICF may need to be revised to reflect the changes to 
the protocol. If the ICF is revised, it must be reviewed and approved by the responsible IRB/ IEC 
and signed by all subjects subsequently enrol led in the clinical study, as well as those currently 
enrolled in the clinical study as applicable.  
10.6. Insurance and Compensation for Injury  
The Sponsor has covered this clinical study by means of an insurance of the clinical study 
according to national requirements. The name and address of the relevant insurance company, the 
certificate of insurance, the policy number and the sum insured are provided in the Investigator’s 
Site File.  
10.7. Protocol Approval and Amendment(s)  
Before the start of the clin ical study, the clinical study protocol and other relevant documents will 
be approved by the IRB /IEC , in accordance with local legal requirements. The Sponsor must 
ensure that all ethical and legal requirements have been met before the first subject is enr olled in 
the clinical study.  
This protocol is to be followed exactly. To alter the protocol, amendments must be written, which 
must be released by the responsible staff and receive IRB /IEC  approval prior to implementation 
(as appropriate).  
Administrative changes may be made without the need for a formal amendment but  will also be 
mentioned in the integrated CSR . All amendments will be distributed to all study protocol 
recipients, with appro priate instructions.  
10.8. Confidentiality Data Protection  
All clinical study findings and documents will be regarded as confidential.  Study documents 
(protocols, IBs and other material) will be stored appropriately to ensure their confidentiality. The 
Principal  Investigator  and members of his/her research team (including the IRB /IEC ) must not 
disclose such information without prior written approval from the Sponsor, except to the extent 
necessary to obtain informed consent from subjects who wish to participate i n the study or to 
comply with regulatory requirements.  
The anonymity of participating subjects must be maintained. Subjects will be specified on study 
documents by their subject number, initial or birth date, not by name. Documents that identify the 
subjec t (e.g., the signed ICF) must be maintained in confidence by the Principal Investigator . 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 59 of 66 09 May 2022 
 10.9. Publication Policy  
By signing the clinical study protocol, the Principal Investigator  agrees with the use of results of 
the clinical study for the purposes of national  and international registration, publication and 
information for medical and pharmaceutical professionals. If necessary, the regulatory  authorities 
will be notified of the Principal Investigator ’s name, address, qualifications and extent of 
involvement.  
A Principal Investigator shall not publish any data (poster, abstract, paper, etc.) without having 
consulted with the Sponsor in advance.  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 60 of 66 09 May 2022 
 11. REFERENCE LIST  
Avau, B., A. Rotondo, T. Thijs, et al. 2015. 'Targeting extra -oral bitter taste recepto rs 
modulates gastrointestinal motility with effects on satiation', Sci Rep , 5: 15985.  
Bray, G. A., G. Fruhbeck, D. H. Ryan, et al. 2016. 'Management of obesity', Lancet , 387: 
1947 -56. 
Chen, M. C., S. V. Wu, J. R. Reeve, Jr., et al. 2006. 'Bitter stimuli in duce Ca2+ signaling and 
CCK release in enteroendocrine STC -1 cells: role of L -type voltage -sensitive Ca2+ 
channels', Am J Physiol Cell Physiol , 291: C726 -39. 
Collaborators, G. B. D. Obesity, A. Afshin, M. H. Forouzanfar, et al. 2017. 'Health Effects of 
Overweight and Obesity in 195 Countries over 25 Years', N Engl J Med , 377: 13 -27. 
Deloose, E., P. Janssen, M. Corsetti, et al. 2017. 'Intragastric infusion of denatonium 
benzoate attenuates interdigestive gastric motility and hunger scores in healthy female 
volunteers', Am J Clin Nutr , 105: 580 -88. 
Guh, D. P., W. Zhang, N. Bansback, et al. 2009. 'The incidence of co -morbidities related to 
obesity and overweight: a systematic review and meta -analysis', BMC Public Health , 
9: 88.  
Hruby, A., and F. B. Hu. 2015. 'T he Epidemiology of Obesity: A Big Picture', 
Pharmacoeconomics , 33: 673 -89. 
Janssen, S., J. Laermans, P. J. Verhulst, et al. 2011. 'Bitter taste receptors and alpha -gustducin 
regulate the secretion of ghrelin with functional effects on food intake and gastr ic 
emptying', Proc Natl Acad Sci U S A , 108: 2094 -9. 
Kim, K. S., J. M. Egan, and H. J. Jang. 2014. 'Denatonium induces secretion of glucagon -like 
peptide -1 through activation of bitter taste receptor pathways', Diabetologia , 57: 
2117 -25. 
Rodgers, R. J. 201 7. 'Bench to bedside in appetite research: Lost in translation?', Neurosci 
Biobehav Rev , 76: 163 -73. 
Rosa -Goncalves, P., and D. Majerowicz. 2019. 'Pharmacotherapy of Obesity: Limits and 
Perspectives', Am J Cardiovasc Drugs , 19: 349 -64. 
Schier, L. A., T. L. Davidson, and T. L. Powley. 2011. 'Ongoing ingestive behavior is rapidly 
suppressed by a preabsorptive, intestinal "bitter taste" cue', Am J Physiol Regul Integr 
Comp Physiol , 301: R1557 -68. 
Sibert, J. R., and N. Frude. 1991. 'Bitterin g agents in the prevention of accidental poisoning: 
children's reactions to denatonium benzoate (Bitrex)', Arch Emerg Med , 8: 1 -7. 
 
  
Aar d var k T hera pe utics, I nc.                                               Cli nical St u d y Pr ot oc ol Versi o n 6. 0  
A A R D -2 0 1 C O N FI D E N TI A L  
 
 Pa ge 6 1  of 6 6  0 9  Ma y  2 0 2 2 
 1 2.  A P P E N DI X  
Pr ot oc ol: A A R D -2 0 1  M M T T  S u bject #: _ _ _ _ _ _ _ _ _ _ _ _ _  
I R B # 2 1 0 2 1 0   
PI: Jere m y Pett us, M D  Date: _ _ _ _ / _ _ _ _ _ _ / _ _ _ _ _ _ _ _  S u bject I niti als:    _ _ _   _ _ _   _ _ _  
 
B o d y C o m p ositi o n  
Ti me: _ _ _ _ _ _ _ _ _ _ _ _  
Hei g ht: _ _ _ _ _ _ _ _ c m                 Wei g ht: _ _ _ _ _ _ _ _ _ _ k g                B MI: _ _ _ _ _ _ _ _  
 
 
B o d y Fat Perce nta ge: _ _ _ _ _ _ _ %  
St u d y Staff  I nitials a n d Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
Vit al Si g ns  
B P a n d He art R ate will be me as ure d i n t he sitti n g p ositi o n. T he s u bject M U S T be reste d f or at le ast 5 mi n.  
 
Ti me S u bject Starts Resti n g: _ _ _ _ _ _ _ _ _ _: _ _ _ _ _ _ _ _ _ _ _  
 
Ar m (circle):       L E F T           RI G H T          
 
Ti me: _ _ _ _ _ _ _ _ _ _ _        Bl o o d Press ure: _ _ _ _ _ _ _ _ _ / _ _ _ _ _ _ _ _ _ _ _ m m H g         Heart Rate: _ _ _ _ _ _ _ b p m  
 
A n y re pe at me as ure me nts of b ot h t he B P a n d he art r ate m ust be t a ke n at le ast 2 mi n . a p art a n d rec or de d.  
 
Ti me: _ _ _ _ _ _ _ _ _ _ _        Bl o o d Press ure:  _ _ _ _ _ _ _ _ _ / _ _ _ _ _ _ _ _ _ _ _ m m H g         Heart Rate: _ _ _ _ _ _ _ b p m  
Res pir at or y R ate :  _ _ _ _ _ _ _ _ _ breat hs/ mi n ute                                    B o d y Te m per at ure : _ _ _ _ _ _ _ _ _ _ _ _ ○C 
St u d y Staff I nitials a n d Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
A E/ S A Es & C o nc o mit a nt Me dic ati o ns  
Di d s u bject ha v e a n y c h a n ges t o t heir c urre nt me dicati o ns?  
*If yes, n ote c h a n ges o n t he c o nc o mit a nt me dic ati o n l o g.   Y E S *    N O  
Di d s u bject re p ort a n y a d verse e v e nts or st u d y relate d pr o ble ms?  
*If yes, n ote c h a n ges o n t he A E/ S A E  l o g.   Y E S *    N O  
St u d y Staff  I nitials a n d Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
  
Aar d var k T hera pe utics, I nc.                                               Cli nical St u d y Pr ot oc ol Versi o n 6. 0  
A A R D -2 0 1 C O N FI D E N TI A L  
 
 Pa ge 6 2  of 6 6  0 9  Ma y  2 0 2 2 
  
B aseli ne  
Di d s u bject f ast 1 0 h o urs as i nstr ucte d ?  
                                                                                                                             
Date of last meal:      _ _ _ _ _/ _ _ _ _ _ _ _ _/ _ _ _ _ _ _ Ti me of last meal:   _ _ _ _ : _ _ _ _                 Y E S      N O  
I nsert I V dr a w li ne i nt o a peri p her al ar m vei n a p pr o xi m atel y o ne h o ur bef ore first 
dr a w.  
St u d y Staff  I nitials a n d Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
Mi xe d Me al T oler a nce Test ( M M T T)  
S C H E D U L E D 
Ti m e p oi nt  T ar g et 
ti m e  
( h h: m m)  A C T U A L 
TI M E  
( h h: m m)  S a m ple(s) c ollecte d / 
T as ks  Y SI Gl uc ose 
re a di n g  
( at e ac h ti me  p oi nt)  
 
Y SI # _ _ _ _ _  N urse 
i niti als  
-1 2 0 mi n    I nstr uct s u bject t o e m pt y bl a d der.  
  
-8 0 mi n    St art I D C # 1:  
 
_ _ _ _ _ _ _ _ _ _ _ _ _  
  
-5 0 mi n    St o p I D C # 1:  
 
_ _ _ _ _ _ _ _ _ _ _ _ _  
  
-3 0 mi n    St u d y Dr u g Gi ve n I F S E C O N D M M T T  
 
Ti m e: _ _ _ _ _ _ _ _ _ _ _  
  
-1 5 mi n    ⃝ Gl uc os e  ⃝ F F A  ⃝ C C K  ⃝ GI P  
  ⃝ I ns uli n  ⃝ Gl uc a g o n  ⃝ P Y Y  ⃝ G L P -1 
⃝ C-Pe pti de  ⃝ G hreli n  ⃝ A m yli n  
  
-5 mi n    ⃝ Gl uc ose  ⃝ I ns uli n  ⃝ C-Pe pti de  
  ⃝ C yt o ki ne p a nel  ⃝ Bile Aci ds/ Ferriti n/ C R P  
⃝ Le pti n/ A di p o necti n  
⃝  6 ml Ser u m st or a ge          ⃝  6 ml Pl as m a  st or a ge          
0 mi n    Gi v e E ns ure li q ui d me al  
( 2 x E ns ure)  
C o ns u m e wit hi n 5 mi n utes  
 
St art Ti m e: _ _ _ _ _ _ _ _ _ _  
 
St o p Ti me: _ _ _ _ _ _ _ _ _ _ _  
  
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 63 of 66 09 May 2022 
 15 min    ⃝ Glucose  ⃝ Insulin  ⃝ C-Peptide  
  
⃝  4 ml Serum storage          ⃝  4 ml Plasma  storage          
30 min    ⃝ Glucose  ⃝ Insulin  ⃝ C-Peptide  
 
  
⃝  4 ml Serum storage          ⃝  4 ml Plasma  storage          
60 min    ⃝ Glucose  ⃝ Insulin  
  ⃝ C-Peptide  ⃝ FFA  
⃝  4 ml Serum storage          ⃝  4 ml Plasma  storage          
SCHEDULED 
Timepoint  Target 
time  
(hh:mm)  ACTUAL 
TIME  
(hh:mm)  Sample(s) collected/  
Tasks  YSI Glucose 
reading  
(at each time 
point)  
 
YSI#_____  Nurse 
initials  
90 min    ⃝ Glucose  ⃝ Insulin  ⃝ C-Peptide  
 
  
⃝  4 ml Serum storage          ⃝  4 ml Plasma  storage          
120 min  
   ⃝ Glucose  ⃝ FFA ⃝ CCK ⃝ GIP 
 
  ⃝ Insulin  ⃝ Glucagon  ⃝ PYY ⃝ GLP -1 
⃝ C-Peptide  ⃝ Ghrelin  ⃝ Amylin  
⃝  6 ml Serum storage          ⃝  6 ml Plasma  storage          
150 min    ⃝ Glucose  ⃝ Insulin  ⃝ C-Peptide  
 
  
⃝  4 ml Serum storage          ⃝  4 ml Plasma  storage          
180 min    ⃝ Glucose  ⃝ FFA 
  ⃝ Insulin  ⃝ C-Peptide  
⃝  4 ml Serum storage          ⃝  4 ml Plasma  storage          
195 min    Start IDC  #2: 
 
_____________  
  
210 min    ⃝ Glucose  ⃝ Insulin  ⃝ C-Peptide  
 
  
⃝  4 ml Serum storage          ⃝  4 ml Plasma  storage          
225 min    Stop IDC #2: 
 
_____________  
  
Aar d var k T hera pe utics, I nc.                                               Cli nical St u d y Pr ot oc ol Versi o n 6. 0  
A A R D -2 0 1 C O N FI D E N TI A L  
 
 Pa ge 6 4  of 6 6  0 9  Ma y  2 0 2 2 
 2 4 0 mi n    ⃝ Gl uc os e  ⃝ F F A  ⃝ C C K  ⃝ GI P  
 
  
 ⃝ I ns uli n  ⃝ Gl uc a g o n  ⃝ P Y Y  ⃝ G L P -1 
⃝ C-Pe pti de  ⃝ G hreli n  ⃝ A m yli n  
⃝  4 ml Ser u m st or a ge          ⃝  4 ml Pl as m a  st or a ge          
A F T E R  fi n al bl o o d dr a w, re m o ve I V.  
N urse c o m pleti n g pr oce d ure Si g nat ure a n d Date: 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Atte n di n g P h ysicia n ( PI/ S u b -I) Si g nat ure a n d Date: 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
P ost -Pr oce d ure  
P ost pr oce d ure m e al e ate n ?                      Y E S      N O          Ti m e: _ _ _ _ _ _ _ _ _ _ _  
P ost -Pr o ce d ure Gl uc ose  C hec k ?                Y E S      N O          Ti m e: _ _ _ _ _ _ _ _ _ _ _           B G: _ _ _ _ _ _ _ _ _  
m g/ d L  
 
                                                                                                            Ti m e: _ _ _ _ _ _ _ _ _ _ _           B G: 
_ _ _ _ _ _ _ _ _  m g/ d L  
A n y A d verse E ve nts t o re p ort d uri n g o r after st u d y pr oce d ure ?   Y E S *    N O  
*If yes, ple ase descri be bel o w:  
 
 
St u d y Staff  I nitials a n d Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
  
Aar d var k T hera pe utics, I nc.                                               Cli nical St u d y Pr ot oc ol Versi o n 6. 0  
A A R D -2 0 1 C O N FI D E N TI A L  
 
 Pa ge 6 5  of 6 6  0 9  Ma y  2 0 2 2 
 P ost -pr oce d ure Vit al Si g ns  
B P a n d He art R ate will be me as ure d i n t he sitti n g p ositi o n. T he s u bject M U S T be reste d f or at le ast 5 mi n.  
 
Ti me S u bject Starts Resti n g: _ _ _ _ _ _ _ _ _ _: _ _ _ _ _ _ _ _ _ _ _  
 
Ar m (circle):       L E F T           RI G H T          
 
Ti me: _ _ _ _ _ _ _ _ _ _ _        Bl o o d Press ure: _ _ _ _ _ _ _ _ _ / _ _ _ _ _ _ _ _ _ _ _ m m H g         Heart Rate: _ _ _ _ _ _ _ b p m  
 
A n y re pe at me as ure me nts of b ot h t he B P a n d he art r ate m ust be t a ke n at le ast 2 mi n . a p art a n d rec or de d.  
 
Ti me: _ _ _ _ _ _ _ _ _ _ _        Bl o o d Press ure:  _ _ _ _ _ _ _ _ _ / _ _ _ _ _ _ _ _ _ _ _ m m H g         Heart Rate: _ _ _ _ _ _ _ b p m  
Res pir at or y R ate :  _ _ _ _ _ _ _ _ _ breat hs/ mi n ute                                    B o d y Te m per at ure : _ _ _ _ _ _ _ _ _ _ _ _ ○C 
St u d y Staff I nitials a n d Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
Ne xt Visit  
 
N E X T VI SI T :  _ _ _ _ _/ _ _ _ _ _ _ _ _ _/ _ _ _ _ _ _ _ _ _ @ _ _ _ _ _ _: _ _ _ _ _ _ _ _  
W as  s u bject gi ve n i nstr ucti o ns f or ne xt visit ?   Y E S   N O  
St u d y Staff I nitials a n d Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
N otes  
 
 
 
 
 
 
 
 
Aardvark Therapeutics, Inc.                                               Clinical Study Protocol Version 6.0 
AARD -201 CONFIDENTIAL  
 
 Page 66 of 66 09 May 2022 
  
 
 
 
 
 
 
 
 
 
 
Study Staff Initials and Date: _____________________________________  
 